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5Abstract
Inherited mitochondrial disorders comprise a phenotypically and genetically
heterogenous group of diseases that are caused by mutations in both mitochondrial
and nuclear genomes. Only symptomatic cure is available for the patients, thus
generating appropriate animal models is essential to understand the underlying
pathological mechanisms and for development of therapeutic approaches.
The transgenic mice with Twinkle-PEO mutations function as a valuable tool for
studying the adult-onset autosomal dominant progressive external ophthalmoplegia
(adPEO). Mice, from the strain referred to as Deletor mice, express a moderately
severe mutation in the mitochondrial DNA helicase Twinkle (Tyynismaa et al.
2005).  The  aim  of  the  diploma  thesis  is  to  study  autophagy  and  mitochondrial
fragmentation in pathogenesis of mitochondrial myopathy in the mouse model for
Twinkle-PEO. The chromosomal insertion site of Twinkle-PEO construct was
localized in the non-coding region (chromosome 16, the C mouse line) and the
construct expressing wild type Twinkle in the gene encoding transmembrane serine
protease 11d (chromosome 5, the A mouse line). The presence of multiple deletions
of mitochondrial DNA (mtDNA) was tested in several Deletor tissues, in particular
the muscle, liver, kidney, testis and intestine and they were proved in the skeletal
muscle and previously also in the brain (Tyynismaa et al. 2005). This result
corresponds with the findings from PEO patients. Changes in the isoform pattern of
Opa1, a crucial protein for a functional mitochondrial network in cells, were also
reported in a case of patients and mouse models with mitochondrial dysfunction
(Duvezin-Caubet et al. 2006). In the Deletor skeletal muscle, all Opa1 isofroms were
found to be slightly elevated with significant increase in the level of L2-OPA1. In
the  brain  tissue,  a  significant  elevation  of  S-OPA1  isoforms  was  detected.  In  the
Deletor skeletal muscle, where autophagy was previously seen by electron
miscroscopy (Tyynismaa et al. 2005), the increased level of autophagy/mitophagy
marker LC3-II was detected. Consistent to autophagy induction, acetylation of
mitochondrial proteins on lysine residues was not increased in the Deletor muscle.
In conclusion, it has been proved that the transgenic disease model faithfully
replicates the features of PEO patients and might help to study the pathogenicity of
Twinkle-PEO mutations and the tissue specificity of mitochondrial disorders.
6Abstrakt
Mitochondriální onemocnění představují fenotypově i geneticky velice heterogenní
skupinu chorob, které mohou být způsobeny mutacemi v mitochondriálním
i jaderném genomu. Jelikož je u pacientů dostupná pouze symptomatická léčba,
vytvoření vhodných myší modelů je nezbytné pro pochopení patogenních
mechanismů u těchto chorob a pro hledání vhodných terapeutických postupů.
Transgenní myši s Twinkle-PEO mutacemi jsou dnes vhodným nástrojem pro
studium autosomálně dominantní progresivní externí oftalmoplegie (adPEO)
s nástupem v dospělosti. Myši z linie označované jako „Deletor“ exprimují mírně
závažnou mutaci v mitochondriální DNA helikáze Twinkle (Tyynismaa et al. 2005).
Hlavním cílem diplomové práce bylo studium autofagie a mitochondriální
fragmentace v patologii mitochondriální myopatie u myšího modelu pro Twinkle-
PEO. Konstrukt Twinkle-PEO byl lokalizován v nekódující oblasti chromozómu
16 (v myší linii C) a konstrukt umožňující nadprodukci „wild type“ formy Twinkle
helikázy v genu kódujícím transmembránovou serin proteázu 11d na chromozómu
5 (v myší linii A). Řada tkání myší linie Deletor (sval, játra, ledviny, varlata a část
střeva) byla testována na přítomnost násobných delecí mitochondriální DNA
(mtDNA). Přítomnost těchto delecí ve svalové a i v již dříve potvrzené mozkové
tkáni (Tyynismaa et al. 2005) odpovídá poznatkům u pacientů s PEO. Změny
v profilu izoforem proteinu Opa1, který je nezbytný pro udržení funkční
mitochondriální sítě v buňkách, byly popsány u pacientů a myších modelů
s mitochondriální poruchou (Duvezin-Caubet et al. 2006). Ve svalové tkáni myší
Deletor byla nalezena mírně zvýšená hladina všech Opa1 izoforem, přičemž nejvyšší
nárůst byl zjištěn u L2-OPA1 izoformy. Mírný nárůst S-OPA1 izoforem byl
detekován v mozkové tkáni. Ve svalu myší Deletor byla zjištěna i zvýšená hladina
LC3-II, proteinového markeru autofagie/mitofagie, což potvrzuje dřívější nálezy
z elektronového mikroskopu (Tyynismaa et al. 2005). V souladu se zvýšenou
hladinou autofagie, nebyla v kosterním svalu myší Deletor nalezena zvýšená
acetylace lyzinových zbytků u mitochondriálních proteinů.
Závěrem, bylo dokázáno, že myší linie Deletor věrně kopíruje fenotyp pacientů
s PEO a je tedy vhodným modelem pro studium patogeneze Twinkle-PEO mutací
a tkáňové specifity mitochondriálních onemocnění.
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∆ψm reduced membrane potential
2D-NAGE two-dimension neutral agarose gel electrophoresis
AA amino acid
AceCS2 acetyl-CoA synthetase 2
ADOA autosomal dominant optic atrophy
ADP adenine nucleotide diphosphate
adPEO autosomal dominant progressive external ophthalmoplegia
AIF apoptosis inducing factor
Ant adenine nucleotide translocator
AT A360T transgenic mouse
Atad3 ATPase family AAA domain-containing protein 3
ATG autophagy related gene
ATP adenine nucleotide triphosphate
BPB bromphenol blue
BSA bovine serum albumin
cDNA coding DNA
CoA Coenzyme A
CoQ Coenzyme Q or ubiquinone
CoQH ubisemiquinone
CoQH2 ubiquinol
COX cytochrome c oxidase
COX- negative cytochrome c oxidase activity
CPEO chronic progressive external ophthalmoplegia
dCK deoxycytidine kinase
DEL Deletor mouse
DF, NF defective fiber, normal fiber
dGK deoxyguanosine kinase
DGUOK gene encoding deoxyguanosine kinase
D-loop displacement loop
DNC deoxynucleotide carrier
dNTP deoxynucleotide triphosphate
dRP deoxyribosephosphate
dsDNA double stranded DNA
ECL enzymatic chemiluminescence
EDTA 2-[2-mDamino)ethyl-(carboxymethyl) amino]acetic acid
EGTA glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
ENT1 equilibrate nucleosite transporter
EtBr ethidium bromide
EtOH ethanol
FADH2 reduced flavin adenine dinucleotide
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GABAA gamma aminobutyric-acid-type-A
GABARAP gamma aminobutyric-acid-type-A-receptor-
associated protein
GATE-16 Golgi-associated ATPase enhancer of 16 kDa
GDH glutamate dehydrogenase
GED GTPase effector domain
GFP green fluorescent protein
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HMG high mobility group
HSP heavy strand promoter
H-strand heavy-strand
IBM inner boundary membrane
IOSCA infantile onset spinocerebellar ataxia
ITH1, ITH2 transcription initiation site for heavy strand, 1 and 2
ITL transcription initiation site for light strand
KSS Kearns-Sayre Syndrome
LHON Leber hereditary optic neuropathy
L-OPA long OPA isoforms
LSP light strand promoter
L-strand light strand
Map-LC3 microtubule-associated protein light chain 3
MEFs mouse embryonic fibroblasts
MELAS mitochondrial encephalomyopathy,
lactic acidosis and stroke-like episodes
MERRF myoclonic epilepsy with ragged red fibers
MPP mitochondrial processing peptidase
MPT mitochondrial permeability transition
mRNA messenger RNA
mtDNA mitochondrial DNA
mTerm mitochondrial transcription termination factor
MTS matrix-targeting sequence
mtSSB proteins mitochondrial single stranded binding proteins
NAD nicotinamide adenine dinucleotide
NADH reduced nicotinamide adenine dinucleotide
NARP neurogenic muscle weakness, ataxia and retinitis pigmentosa
NCR non-coding region
nDNA nuclear DNA
OH origin of heavy strand replication
OL origin of light strand replication
OM outer membrane
Opa1 dynamine-related guanosine triphosphatase
Ori-Z broad origin zone
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OXPHOS oxidative phosphorylation
PARL mitochondrial rhomboid protease
PCR polymerase chain reaction
PE phosphatidylethanolamine
PEO progressive external ophthalmoplegia
Polγ mitochondrial DNA polymerase gamma
Polrmt mitochondrial RNA polymerase
PS Pearson Marrow-Pancreas Syndrome
PT permeability transition
PVDF polyvinylidene fluoride
RIs replication intermediates
RITOLS RNA-incorporation throughout the lagging strand
ROS reactive oxygen species
RRF ragged-red fibers
rRNA ribosomal RNA
SBG Serva Blue G
SDH succinate dehydrogenase
SDH+ positive succinate dehydrogenase activity
SDS sodium dodecyl sulfate
SDs standard deviations
SDS-PAGE SDS-polyacrylamide gel electrophoresis
Sir2 silent information regulator 2
Sirt family silent information regulator two family
S-OPA short OPA1 isoform
ssDNA single stranded DNA
SUCLA2 succinyl coenzyme A-ligase
TBS-T Tris-buffer saline - 0.1% Tween 20
TCA cycle tricarboxylic acid cycle
Tfam mitochondrial transcription factor A
Tfb1m mitochondrial transcription factor B1
Tfb2m mitochondrial transcription factor B2
TK1 thymidine kinase 1
TK2 thymidine kinase 2
TM domain transmembrane domain
Top1mt mitochondrial topoisomerase I
tRNA transfer RNA
WT wild type
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1. Introduction
Mitochondria are key organelles that play a central role in several cellular processes,
in particular energetic metabolism, homeostasis, cell division, growth and death.
Their crucial function is a production of ATP by oxidative phosphorylation
(OXPHOS) process that requires activity of five multimeric enzyme complexes
embedded in the inner mitochondrial membrane. Disruption of this energy supply
can have devastating consequences for the cell, organ or individual. Mitochondria
possess their own multicopy genome, which is maternally inherited. Only 13 from
approximately 80 subunits of OXPHOS complexes are encoded by the
mitochondrial  genome,  whereas  the  rest  of  the  subunits  as  well  as  all  proteins  and
enzymes involved in mitochondrial metabolism and mtDNA maintenance are
encoded by the nuclear genome. Mutations in both mitochondrial DNA (mtDNA)
and nuclear DNA (nDNA) have been identified as causative in number of
multisystematic disorders, cancer, obesity and diabetes (Wallace 2005).
Twinkle, the only known mitochondrial DNA helicase, plays an essential role in the
mtDNA maintenance (Spelbrink et al. 2001). Adult-onset progressive external
ophthalmoplegia (PEO) is a mitochondrial disease with Mendelian inheritance that is
caused by mutations in nuclear genes encoding mtDNA maintenance proteins and
characterized by the presence of multiple mtDNA deletions in patients´ tissues
(Zeviani et al. 1989).  PEO patients with mutations in the gene encoding Twinkle
helicase explain about 35% of autosomal dominant PEO cases (Lamantea et al.
2002). The “Deletor” mouse, a transgenic animal model for late-onset PEO with
autosomal dominant mutation in Twinkle (Tyynismaa et al. 2005), mimics closely
the PEO patients´ phenotype and is a tool to study the disease at a presymptomatic
phase or to test different drugs for therapy approach. The experimental trials lead to
better understanding of the pathogenic role of either mtDNA or nDNA mutations in
mitochondrial disorders.
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2. Aims of the thesis
The mouse model for studying late-onset mitochondrial disease was generated in
2005 in the laboratory of Prof. Anu Suomalainen (Tyynismaa et al. 2005). The
general characterization of the transgenic mouse clearly showed its potential as
a tool to study late-onset mitochondrial disease. The histological and molecular
findings, for example COX negative/ SDH positive cells and accumulation of
multiple mtDNA deletions in particular tissues, closely mimicked the findings in
PEO patients (Suomalainen et al. 1997). Moreover, several structural changes of
mitochondria have been found in the affected muscle fibers that have pointed to
putative induction of autophagy/ mitophagy (Tyynismaa et al. 2005). This study is
based on previous findings obtained from this mouse model.
The aim of the study was to further characterize the phenotype of the transgenic
mice in detail. My specific aims were:
· To determine the chromosomal insertion site of the Twinkle transgene in the
genome of two different transgenic mouse lines
· To study the presence of mitochondrial DNA deletions in variety of Deletor
tissues
· To examine the respiratory deficient phenotype in proliferative tissue of the
Deletor mice
· To study the role of autophagy and mitochondrial fragmentation in
mitochondrial myopathy pathogenesis using appropriate protein markers
such as LC3 or Opa1
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3. Review of literature
3.1 Mitochondria
Mitochondria are essential cytoplasmic organelles existing in almost of all
eukaryotic cells. According to the original endosymbiotic theory, mitochondria are
direct descendents of the α-proteobacteria that became endosymbiont in a nucleus-
containing but amitochondrial host cell (Margulis 1976). Whether the host cell
already contained a nucleus is not clear, however the host cell provided the nuclear
genome for subsequent transfer of genes related to mitochondrial biogenesis and
function  to  nucleus  (Gray et al. 1999). In 1998, a new hypothesis about
mitochondrial origin in eukaryotes has been proposed. The hydrogen hypothesis
assumes that eukaryotes originated through symbiotic metabolic association called
syntrophy where strictly anaerobic archaebacterium dependent on hydrogen became
a host of ancestral mitochondria, a fermentative α-proteobacterium that was able to
respire and generated hydrogen and carbon dioxide as waste products (Martin and
Muller 1998).
3.1.1 Structure and function of mitochondria in cells
Mitochondria in cells form a complex interconnected reticulum that is highly
dynamic and interacts with other cellular components, in particular the cytoskeleton
and endoplasmic reticulum (Mannella 2000). The main characteristics of these
organelles, such as size, shape, mass or distribution may vary markedly between
different cells or tissues with different energetic needs. Moreover, it has been
demonstrated that functional mitochondria can be transferred to the target cells to
rescue the mitochondrial functions (Spees et al. 2006).
Mitochondria are cellular organelles bounded by two membranes: the outer and
inner membrane. The smooth outer membrane (OM) includes diverse set of
enzymes, proteins controlling morphology of the organelle, members of the pro- and
anti-apoptotic family as well as pore-forming components (porins) which allow the
free passage for molecules up to 5 kDa. Complicated inner membrane consists of the
inner boundary membrane (IBM) apposed to the OM and the crista membrane
protruding as tubules or lamellae into the matrix of the organelle (figure 3.1). All
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cristae are connected to the inner boundary membrane and to each other by a tubular
structure called crista junctions with variable length but relatively constant diameter
of 28 nm within a variety of healthy cells types (figure 3.1; Frey and Mannella
2000). This subdivision defines topologically distinct compartments, the
intermembrane space between the outer and inner membrane, where enzyme for
further ATP utilization are localized, and the mitochondrial matrix that includes
multiple copies of mitochondrial DNA and several hundreds of proteins that
participate in mitochondrial functions, such as citric acid cycle, biogenesis of heme,
fatty acid oxidation, electron transport with energy transduction and Ca2+ reservoir.
Figure 3.1: Mitochondria in cells. A, the entire computer model from segmented
3D tomograms showing cristae (in yellow), the inner boundary membrane (in light
blue) and the outer membrane (in dark blue, Frey and Mannella 2000). B, fluoro-
colored picture of bovine pulmonary cells, nucleus is visualized with DAPI (blue),
mitochondria with FITC (red) and actin with TRITC (green, modified from
www.rpgroup.caltech.edu/courses/PBL/size.htm), C, electron microscope image, D,
drawing of the mitochondria, the structures are pointed (modified from
homepages.cwi.nl/.. ./SiC/PICT/mitochondria.JPG).
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3.1.1.1 The oxidative phosphorylation system
The main function of the inner boundary membrane is to enclose the matrix space
and to transport ions, substrates and proteins through the specific carriers. The crista
membrane, in form of tubules opened to the intermembrane space, is predominantly
associated with oxidative phosphorylation (OXPHOS) and ATP production
(Gilkerson et al. 2003). The OXPHOS system is organized into the four enzyme
complexes (complex I-IV) that comprise electron-transport chain, also called
mitochondrial respiratory chain, and the ATP synthase complex (complex V), which
uses the free energy generated by electron transport along the respiratory chain to
produce ATP. The subunits of the five enzyme complexes are encoded in both the
nuclear and mitochondrial genome (figure 3.2, 3.3).
The electrons are generated from two coenzymes NADH and FADH2 rising from
degradation of pyruvate in citric acid cycle and fatty acid oxidation. NADH donate
the electrons to complex I (NADH-ubiquinone oxidoreductase), the largest
OXPHOS  complex  composed  of  45  subunits,  seven  of  which  are  encoded  by
mitochondrial DNA (Carroll et al. 2006). Complex II (Succinate: Coenzyme
Q Oxidoreductase, SDH) that comprises of four subunits all of which are encoded by
nuclear DNA, accepts the electrons donated from FADH2. Complex I and Complex
II  pass  the  electrons  to  Coenzyme  Q  (CoQ  or  ubiquinone)  and  along  the
ubisemiquinone (CoQH) to Coenzyme QH2 (CoQH2 or ubiquinol).  Coenzyme QH2
transfers the electrons to Complex III (Coenzyme Q: Cytochrome c Oxidoreductase)
consisting of 11 subunits, only one of which is encoded by mitochondrial genome.
Complex III then reduces cytochome c, a mobile hydrophobic hemoprotein that
transfers the electrons to Complex IV (Cytochome c Oxidase, COX) comprising of
three mitochondrial and 10 nuclear encoded subunits. Complex IV catalyzes
reduction of O2, the terminal acceptor of the electrons, to produce H2O (figure 3.2).
The transfer of the electrons along the respiratory chain is utilized by Complex I, III
and IV to transport protons from matrix to the intermembrane space and to generate
an electrochemical gradient. Complex V (FO/F1 ATP synthase) that consists of 12-14
subunits of which two are encoded by mitochondrial genome, catalyzes the
phosphorylation of ADP to ATP, using the energy of the protonic influx into the
mitochondrial matrix through the channel in the structure of Complex V (figure 3.2).
This process is also called energy transduction. ATP, a molecule capturing free
energy for most of the energy-dependent cell processes, is released from
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mitochondria through the adenine nucleotide translocator (Ant). The reactive oxygen
species (ROS), dangerous by-products of OXPHOS, are results from the
misdirection of the electrons directly to O2 in early stages of respiratory chain. ROS
are responsible for oxidative damage of proteins, lipids and amino acids within
mitochondria, but also have important roles in cell signaling.
Figure 3.2: Creative drawing of the respiratory chain embedded in the cristae
membrane. The mitochondrially encoded subunits of each complex are shown in
different  colors:  complex  I  –  blue,  complex  II  –  green,  complex  IV  –  red  and
complex V – yellow. The colors correspond to genes in mitochondrial DNA shown
in figure 3.3,  Cyc c – cytochorome c,  CoQ -  coenzyme Q (modified from Zeviani
and Di Donato 2004).
3.1.1.2 Cycles of aerobic metabolism in mitochondria
The citric acid cycle, alternatively known as tricarboxylic acid (TCA) cycle or the
Krebs cycle, is a common pathway for the aerobic oxidation of lipids, carbohydrates
or proteins. Here, the final product acetyl-CoA is oxidized while the coenzymes
(NADH and FADH2), subsequently utilized in the respiratory chain and ATP
production, are reduced. The enzymes of this main amphibolic cycle are localized in
mitochondrial matrix, either free or associated with the inner membrane.
In humans, the oxidation of fats is quantitatively more important than glucose
oxidation as a source of ATP. The fatty acid oxidation or β-oxidation is a process
requiring  oxygen for  oxidation  of  fatty  acyl-CoA to  yield  acetyl-CoA,  NADH and
FADH2 in each cycle. That generates about six times more ATP than the oxidation
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of the same amount of glycogen. Starvation causes increase of fatty acid oxidation
that leads to production of ketone bodies by the liver (ketosis).
In addition to the production of energy supply, mitochondria play a key role in
several biosynthetic pathways, such as synthesis of heme, nucleotides, amino acids
or steroid hormones, regulation of calcium homeostasis or heat production.
3.1.2 Mitochondrial genome
Mitochondrial genome is polyploid and consists of hundreds to thousands copies of
mitochondrial DNA (mtDNA) per cell. Several specific features distinguish
mitochondrial genetics from the nuclear one. The sequence and the gene
composition of human mtDNA is highly homologous to mouse mtDNA (Bibb et al.
1981).
Unlike the nuclear DNA (nDNA), mtDNA is a circular, double-stranded molecule
comprising 16,569 bp that is organized in stable nucleoprotein complexes, called
mitochondrial nucleoids that are devoid of histones (Spelbrink et al. 2001). These
dynamic structures stabilize and protect mtDNA and are able to redistribute into the
daughter cells as units of the mitochondrial inheritance (Garrido et al. 2003).
Mitochondrial genome is strictly maternally inherited. However, paternally derived
mtDNA deletion in muscle has been identified in patient with mitochondrial
myopathy (Schwartz and Vissing 2002), but the occurrence of paternal inheritance is
rare event (Schwartz and Vissing 2004).
Fundamental aspect of mitochondrial genetics is homoplasmy and heteroplasmy.
Normal individuals contain an identical genotype of mtDNA population, a state
called homoplasmy. Heteroplasmy occurs when cells or tissues harbor a mixture of
two or more mtDNA variants. Homoplasmic mutations affect whole population of
mtDNA, whereas heteroplasmic mutations are present only in some copies of
mtDNA. The proportion of mutant mtDNA may range from 0% to 100%. For
expressing the clinical signs and biochemical defects of oxidative dysfunction, the
mutant portion must reach a minimum critical level, called threshold that for tRNA
mutations is over 90% and only 40 - 60% mutant mtDNA for deletion (Rossignol et
al. 2003).  The  threshold  effect  for  the  disease  onset  is  lower  in  tissues  with  high
energy demands, such as heart, brain, skeletal muscle and retina.
In the presence of heteroplasmy, population of mitochondria is randomly distributed
to the daughter cells during mitosis. The proportion of mutant mtDNA in daughter
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cells may shift and the phenotype can change in time and vary between tissues. This
phenomenon is known as mitotic segregation and may explain tissue-specific variety
of symptoms common for mtDNA-related diseases (reviewed by Taylor and
Turnbull 2005). Experiments with heteroplasmic mice have shown that mtDNA
segregation is under nuclear control (Battersby et al. 2003).
3.1.2.1 Mitochondrial DNA
Mitochondrial DNA, first sequenced in 1981, has highly conserved structure and
gene organization among mammals (Anderson et al. 1981). Using denaturing cesium
chloride gradient, the strands of mtDNA duplex can be distinguish due to their
different G + T base composition. The heavy strand (H-strand) comprises higher
level of guanine compare to the higher level of cytosine involved in the light strand
(L-strand, Kasamatsu and Vinograd 1974).
Figure 3.3: Map of human mitochondrial DNA.  The  outer  circle  represents  the
H-strand, containing the majority of genes. The certain colors of genes correspond to
particular colors of the subunits in figure 3.2. The inner circle represents the
L-strand.  The  rRNA  genes  and  D-loop  are  also  shown  in  color.  The  origins  of
H-stand (OH) and L-strand (OL)  replication  and  direction  of  DNA  synthesis  are
indicated by thick bent arrows; the transcription sites (ITH1, ITH2, IT L) and direction
of RNA synthesis are marked by thin bent arrows. The binding site for transcription
terminator is denoted.
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MtDNA contains 37 genes that encode 13 polypeptides, two ribosomal RNAs (12S
rRNA  and  16S  rRNA)  and  22  transfer  RNAs  (tRNAs).  All  the  mtDNA-encoded
proteins are essential components of multimeric OXPHOS complexes: seven of
them (MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5 and MT-ND6)
are subunits of complex I, one (cytochrome b, CYT B)  of  complex  III,  three  (MT-
CO1, MT-CO2 and MT-CO3) of complex IV and two (MT-ATP6 and MT-ATP8) of
complex V (figure 3.3). The remaining subunits of these complexes, all subunits of
complex II as well as all proteins involved in mtDNA expression and its regulation
are encoded by nDNA  (reviewed by  Taanman 1999).
The mtDNA genes lack introns and most of intergenetic sequences as well as some
of the protein termination codons are missing. Both rRNAs and tRNAs molecules
are atypically small, thus they usually separate the protein genes from each other
(Ojala et al. 1981).
The major regulation site of mtDNA is called the displacement loop (D-loop) and
spans approximately 1000 bp, situated between the genes for tRNAPhe and tRNAPro
(Shadel and Clayton 1997). The triple-stranded D-loop structure is assembled from
mtDNA duplex and a short H-strand segment annealed to the L-strand (figure 3.3).
The  D-loop  is  a  part  of  the  main  non-coding  region  (NCR)  containing  the  key
regulatory elements for mtDNA replication and translation (H-strand and L-strand
transcription promoters, HSP and LSP, respectively, and origin of H-strand
replication, OH), conserved sequence blocks and termination-associated sequences
(Shadel and Clayton 1997).
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3.2 MtDNA maintenance
3.2.1 Proteins of mtDNA maintenance
Only some of mtDNA molecules organized into mitochondrial nucleoids are actively
replicated/ transcribed at the same time (He et  al. 2007). Proteins maintaining
mtDNA stability and expression are included in nucleoids composition, encoded by
the nuclear genome and imported into mitochondria. Spontaneous or inherited
pathogenic mutations in most of these proteins result in mtDNA defects in form of
deletions, depletions or point mutations, which cause heterogeneous mitochondrial
disorders. The construed list includes mtDNA maintaining proteins that directly or
indirectly associate and influence mtDNA.
3.2.1.1 Mitochondrial DNA polymerase gamma
The key component of mtDNA maintenance is mitochondrial DNA polymerase
gamma (Polγ) that is responsible for DNA synthesis in all replication, repair and
recombination processes in animal cell mitochondria (Ropp and Copeland 1996).
The human Polγ functions as heterotrimer consisting of catalytic subunit PolγA of
139 kDa, encoded by POLG1 gene  on  chromosome  15q24,   and  a  homodimer  of
accessory subunit PolγB of 53 kDa, coded by POLG2 gene  on  chromosome  17q
(Yakubovskaya et al. 2006). The catalytic subunit possesses both DNA polymerase
and proofreading (3´-5´ exonuclease) functions. The C-terminal polymerase domain
(pol-domain) is separated from N-terminal exonuclease domain (exo-domain) by
a spacer or linker region. In addition, PolγA shows 5´-deoxyribosephosphate (dRP)
lyase activity that is necessary for mtDNA repair through base excision repair
pathway (Graziewicz et al. 2006). A functional binding of accessory subunit Polγ to
the linker region of catalytic polypeptide stimulates its polymerase and proofreadng
activity, enhance DNA binding and holoenzyme processivity (Fan et al. 2006).
Pathogenic mutations in both POLG1 and POLG2 genes  have  been  identified  to
underlie several neurodegenerative disorders (http://tools.niehs.nih.gov/polg/).
3.2.1.2 Mitochondrial DNA helicase - Twinkle
Twinkle is the only known mtDNA helicase which plays a key role in the mtDNA
replication and maintenance in mammalian cells. The human protein that displays
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striking similarity to bacteriophage T7 gene 4 primase/helicase (gp4), is encoded by
PEO1 gene (C10orf2) on chromosome 10q24 and consists of 684 amino acids (AA)
that are encoded by five exons. Human splice variant called Twinky lacks part of the
C-terminal helicase domain, but terminates with four unique amino acids that do not
permit to form multimers (Spelbrink et al. 2001). The C-terminal helicase domain of
Twinkle protein contains highly conserved Walker A and Walker B motifs involved
in ATP binding and hydrolysis (figure 3.4). In contrast, function of the N-terminal
region, homologous to T7 primase domain has not been assessed yet. Recently, its
role in efficient binding to ssDNA has been demonstrated, although its presence in
DNA helicase activity is not absolutely required (Farge et al. 2008). The linker
region, present between primase and helicase domains, is required for
multimerization and helicase activity (figure 3.4). Human protein is ubiquitously
expressed with the highest level in the skeletal muscle (Spelbrink et al. 2001). The
Twinkle colocalizes with mtDNA in mitochondrial nucleoid structures in stable
hexameric form that catalyzes ATP-dependent unwinding of dsDNA in
5´-to-3´ directionality. Together with Polγ and mitochondrial single-stranded
binding (mtSSB) proteins can create minimal mammalian mtDNA replisome to
generate 16 kb dsDNA corresponding to full-length human mtDNA molecule
(Korhonen et al. 2004).
Figure 3.4: Schematic picture of the Twinkle protein. Predicted presequence and
primase-related domain, which is similar to primase of bacteriophage T7, are
possessed on the N-terminal part. The C-terminal helicase domain containing
conserved Walker A and Walker B motifs is separated from the “primase” domain
by the linker region.
 Mutations in PEO1 gene have been linked to several mitochondrial diseases
associated with defects in mtDNA. Most of them cluster in the linker region and
their implication on mtDNA maintenance have been recently studied using a three-
dimensional Twinkle model (Korhonen et al. 2008). They have investigated that
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some of the mutations absolutely abolish protein hexamerization and DNA helicase
activity in vitro whereas others show only mild effects (Korhonen et al. 2008).
However, experiments in cellular context have given slightly different results,
consistent with late-onset phenotype suggesting mild functional defect (Goffart  et al.
2009)
3.2.1.3 Mitochondrial single-stranded DNA binding protein
Human mitochondrial single-stranded DNA binding (mtSSB) protein of 132 AA,
encoded on chromosome 7q34, forms a homotetramer that stabilizes the ssDNA
during mtDNA replication (Tiranti et al. 1995). Stimulation of primer recognition
and both DNA polymerase and proofreading activity of Polγ by mtSSB proteins
enhance the mtDNA replication fidelity (Farr et al. 1999).  Two  new  functions  of
mtSSB proteins in mitochondrial morphology maintenance have been proposed.
MtSSB proteins have been suggested to regulate mitochondrial fusion and fission
reaction and cellular response to apoptotic stimulation (Arakaki et al. 2006).
3.2.1.4 Adenine nucleotide translocator
The adenine nucleotide translocator (Ant), a channel embedded in the inner
mitochondrial membrane, is responsible for exchange of intramitochondrial ATP for
cytoplasmic  ADP  and  consequently  controls  the  ATP  supply  of  the  cell.  The  Ant
functions as a dimer of 30 kDa polypeptides encoded by SLC25A4 gene  on
chromosome 8 and has multiple isoforms with tissue-specific expression in
mammals (Stepien et al. 1992). Human Ant1 is mainly expressed in heart and
skeletal muscle, Ant4 in testis, Ant2 is either absent or expressed in proliferating
tissues, while Ant3 is ubiquitously expressed. In contrast, three mouse Ant isoforms
are homologous to the human Ant1, Ant2 and Ant4, but only expression pattern of
Ant1 corresponds to Ant1 in humans (Levy et al. 2000; Dolce et al. 2005).
Dominant mutations in SLC25A4 gene  affect  its  functions  in  mtDNA  maintenance
and cause mitochondrial diseases (Kaukonen et al. 2000).
3.2.1.5 Mitochondrial transcription factor A
Mitochondrial transcription factor A (Tfam) represents one of the main components
of mitochondrial nucleoids and mtDNA maintenance.  This 162-AA protein encoded
by TFAM gene on chromosome 10q24, possesses two tandem HMG box domains
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with DNA-binding properties that are necessary to enhance promoter-specific
transcription of mtDNA together with mitochondrial transcription factor B1 and B2
(Dairaghi et al. 1995; Falkenberg et al. 2002). The amount of Tfam in mammalian
cells closely correlates with amount of mtDNA but not with the transcription level
due to the proposal model where mtDNA replication is coupled with mtDNA
transcription (Kanki et al. 2004; Pohjoismaki et al. 2006). In mammals, Tfam can
entirely cover and pack mtDNA to form nucleoid structures associated with
mitochondrial inner membrane (Alam et al. 2003).
3.2.1.6 Mitochondrial DNA topoisomerase I
In mammalian cells, the mitochondrial topoisomerase I (Top1mt) is the only
mitochondrial-specific enzyme responsible for maintaining mtDNA topology during
replication and transcription. Top1mt that belongs to type IB topoisomerases is
encoded on chromosome 8q24.3 and shows striking sequential and biochemical
similarity to nuclear topoisomerase I except the mitochondrial targeting sequence in
the N-terminal domain (Zhang et al. 2001). Human topoisomerase IIIα (hTop3α) has
dual cellular localization due to its two potential start codons. The 1 001-AA isoform
resides to mitochondria and 976-AA isoform to nucleus (Wang et al. 2002).
3.2.1.7 ATPase family AAA domain-containing protein 3
Recently, ATPase family AAA domain-containing protein 3 (Atad3) has been
identified as DNA binding protein present in mitochondrial nucleoids that associate
with mitochondrial inner membrane (He et al. 2007). This 72 kDa protein encoded
on chromosome 1p36.33, preferentially binds to triple-stranded region of D-loop
(7S DNA) but its variable amounts associated with mitochondrial nucleoids suggest
only transient binding to subpopulation of mtDNA. The proposed role of Atad3 in
mitochondria is in nucleoids formation and segregation (He et al. 2007).
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3.2.2 Mitochondrial DNA replication and expression of
mtDNA genes
3.2.2.1 MtDNA replication
Replication of mtDNA situated in the mitochondrial matrix proceeds throughout the
cell cycle and also in post-mitotic cells. For more than 20 years, it had been believed
to proceed by generally accepted strand-asynchronous, asymmetric mechanism
(Clayton 1982). Recently, this orthodox model has been challenged by presenting
new findings utilized by two-dimensional neutral agarose gel electrophoresis
(2D-NAGE; Holt et al. 2000; Bowmaker et al. 2003).
In the strand-asynchronous model where the mtDNA molecules are replicated
unidirectionally from two independent and temporally distinct origins, the DNA
synthesis starts at OH which is located downstream of the LSP in the D-loop region.
It proceeds along the parental L-strand to produce full daughter H-strand. At
two-thirds  of  the  way  from  OH, the replication fork reaches a 30-nucleotide long
non-coding region which contains the origin of L-strand (OL, figure 3.3). When
parental H-strand is displayed, the L-strand origin is exposed and synthesis of
daughter L-strand is initiated in the opposite direction (reviewed by Taanman 1999).
The evidences that support asymmetrical model have been reported using atomic
force microscopy and 2D-NAGE (Brown et al. 2005). Moreover, Brown et al have
suggested  that  some  of  the  mtRNAs,  in  form  of  R-loops,  stably  associate  with
mitochondrial dsDNA throughout the circular genome (Brown et al. 2008).
Replication in the strand-coupled model begins exclusively at or near the OH and
proceeds unidirectionally around the entire mtDNA molecule. In this model, mtDNA
replication intermediates (RIs), called RITOLS (an acronym for RNA-incorporation
throughout the lagging strand), consist of RNA-DNA hybrids that might function as
primers for maturation of L-strand DNA that iniciates from the previsously
designated OL (Holt et al. 2000; Yang et al. 2002; Yasukawa et al. 2006). This
model can also explain the findings from 2D-NAGE (Brown et al. 2005). Further
analysis of replication intermediates has demonstrated that strand-coupled
replication of mtDNA initiates bidirectionally in the broad origin zone (ori-Z)
spanning 4-6 kbp downstream of the major non-coding region (NCR). After the
replication fork arrest at OH, the replication intermediates of ongoing synthesis are
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undistinguishable from RIs in the unidirectional mechanism (Bowmaker et al. 2003).
It seems that replication modes might be tissue-specific and/or different modes
operate in the same cells, however the exact consensual mechanism of mtDNA
replication as well as the incorporation of ribonucleotides into the RIs remains
undetermined.
3.2.2.2 Transcription of mtDNA and translation of mitochondrial genes
The expression mode of mitochondrial genes reflects the peculiar features of
mitochondrial genome structure. Transcription of H-strand is initiated from distinct
sites as two overlapping units: the initiation site H1 (ITH1), located 19 nt upstream of
the gene for tRNAPhe, produces a short polycistron that covers two rRNA genes and
terminates at the end of the gene for 16S rRNA (figure 3.3). This transcript is
produced 25 times more frequently than a long H-strand polycistron that starts at the
initiation  site  H2  (ITH2),  close  the  5´-end  of  gene  for  12S  rRNA.  The  long
polycistronic molecule corresponds to almost whole H-strand, covering two
12 tRNA genes and 12 polypeptides genes. The initiation site for L-strand (ITL),
localized 150 bp from ITH1, gives arise to single polycistronic molecule that derives
eight  tRNAs  and  the  ND6  mRNA  (figure  3.3;  Montoya et al. 1983). The
mitochondrial H-strand and L-strand promoters (HSP and LSP, respectively) where
the H1 and L initiation sites are located, contain enhancer elements immediately
upstream to the initiation points as well as binding sites for specific transcription
factors. Mitochondrial transcription is catalyzed by monomeric mtRNA polymerase
(Polrmt) that requires Tfam and one of mitochondrial transcription factor B
paralogues, Tfb1m or Tfb2m (Falkenberg et  al. 2002). Only the transcription of
short H-strand polycistron is specifically terminated by mitochondrial transcription
terminator (mTerm), a 39 kDa protein that binds to 3´-end of tRNALeu and
constitutes the physical barrier for RNA polymerase (figure 3.3; Kruse et al. 1989).
Translation of mtDNA genes takes place on mitochondrial ribosomes or
mitoribosomes that are localized in the matrix of the organelle and consist of 12S
and 16S rRNAs encoded by mtDNA, and several proteins encoded by nuclear DNA.
Mitochondria use modified genetic code with simplified decoding mechanism. The
mitochondrial  tRNAs and  rRNAs are  very  small  and  tRNA genes  flank  all  protein
and rRNA genes to produce mature RNAs by processing the long polycistronic
transcripts. Mitochondrial mRNAs lack the specific features of other mRNAs such
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as 5´ and 3´-untranslated regions (might have 1-3 nt at untranslated 5´-end),
3´ polyadenylation signal (polyadenylation tail of 55 A residues starts immediately
after stop codon) or 7-methylguanosine cap structure at 5´-end (Montoya et al. 1981,
reviewed by Fernandez-Silva et al. 2003).
3.2.3 Mitochondrial nucleotide metabolism
For  both  nuclear  and  mitochondrial  DNA  synthesis,  the  pool  of  the  precursors,
deoxyribonucleotide triphosphates (dNTPs), is fundamental. On the basis of the
actual stage of a cell or tissue, two separate pathways can salvage the mitochondrial
dNTP  pool  with  dNTPs.  In  growing  or  proliferative  cells  where  nuclear  DNA  is
replicated during the S-phase, the synthesis of dNTPs occurs de novo in  cytosol
(Reichard 1988). Here, two deoxynucleoside kinases: thymidine kinase 1 (TK1) and
deoxycytidine kinase (dCK) phosphorylate deoxynucleosides to produce
deoxynucloside monophosphates that are either transported to nucleus for nDNA
replication or in form of diphosphates by the deoxynucleotide carrier (DNC) into the
mitochondria (Dolce et al. 2001; Elpeleg 2003). In terminally differentiated or non-
dividing cells the replication of nDNA does not occur and dNTP synthesis in cytosol
is inhibited, deoxynucleosides for mitochondrial pool can be salvaged from
extracellular fluid and intracellular degradation. In this salvage pathway,
deoxynucleosides are introduced to mitochondrial matrix by equilibrate nucleoside
transporter 1 (ENT1) and phosphorylated by mitochondrial deoxynucleoside
kinases: thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK, Ferraro et al.
2005). Hence, replication of mtDNA proceeds throughout the cell cycle,
independently on the nuclear DNA replication, and because mitochondrial dNTP
pool is separated from the cytosol by impermeable inner mitochondrial membrane
(Bestwick and Mathews 1982), the second salvage pathway becomes extremely
important in case of non-dividing cells, such as in post-mitotic tissues (Pontarin et
al. 2003). A balance of the four dNTPs in mitochondrial pool is essential for fidelity
of mtDNA replication machinery, since several human diseases arise from inherited
enzymatic deficiencies of either cytosolic or mitochondrial dNTP metabolism.
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3.3 Opa1 protein and mitochondrial fragmentation
The Opa1 protein has been recently described as dynamin-related GTPase encoded
in humans by the optic atrophy 1 (OPA1) gene on chromosome 3q28 (Delettre et al.
2000). The gene which spans more than 90 kbp, is composed of 30 coding exons and
due to alternative splicing of either exon 4, 4b or 5b generates at least eight mRNA
Opa1 isoforms. Particular isoforms are ubiquitously expressed throughout the human
tissues (in the heart, skeletal muscle, liver, testis, kidney), predominantly in the brain
and retina (Delettre et al. 2001; Olichon et al. 2007). The first heterozygous
mutations in OPA1 gene have been linked to autosomal dominant optic atrophy
(ADOA, OMIM 165500), the most common non-syndromic mitochondrial
hereditary optic neuropathy. So far, over 117 different mutations in the OPA1 gene
have been described causing ADOA (http://lbbma.univ-angers.fr/eOPA1/). Recently,
optic atrophy with neuromuscular involvement, chronic PEO and the accumulation
of multiple mtDNA deletions in the skeletal muscle, referred to as OPA1 ´plus´
syndrome has been characterized (Amati-Bonneau et al. 2008; Hudson et al. 2008).
3.3.1 Structure of Opa1 protein
The Opa1 protein, a large GTPase related to dynamin family, is localized to the
inter-membrane space and associated with the inner mitochondrial membrane
(Olichon et al. 2002). The Opa1 orthologs, the Msp1p in Schizosaccharomyces
pombe (Pelloquin et al. 1999) and the Mgm1p in Saccharomyces cerevisiae
(Shepard and Yaffe 1999) that are anchored to the matrix side of the inner
membrane or to the outer membrane, respectively, are involved in mitochondrial
morphology and maintenance. The Opa1 protein displays a coiled-coil C-terminal
domain corresponding to the dynamin GTPase effector domain (GED) that is
involved in catalytic activation, and the GTPase domain with three GTP-binding
motifs and a dynamin signature. The N-terminal transmembrane domain (TM) is
required for targeting the protein to the mitochondrial inner membrane (figure 3.5;
Olichon et al. 2007; Akepati et al. 2008).
The function of Opa1 protein and its role in mitochondrial fragmentation is regulated
by mitochondrial membrane potential (∆ψm)  and  correlates  with  processing  of
several Opa1 isoforms with distinct molecular sizes. mRNAs splice forms are
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synthesized as precursors with the matrix-targeting signal (MTS) followed by
a transmembrane domain. The N-terminal MTS is cleaved by the mitochondrial
processing peptidase (MPP) during the import to form the mature long Opa1
isoforms (L-OPA1). Each long isoform, encoded by one of the eight mRNA splice
forms,  undergoes further processing at S1 cleavage site and some also a more
C-terminal S2 cleavage site (in alternative exon 5b) to produce one or more short
Opa1 isoforms (S-OPA1). It has been suggested that mitochondrial fusion depends
only on L-OPA1 isoforms (Ishihara et al. 2006). Conversely, Song et al. found that
mixture of long and short isoforms is important for efficient mitochondrial fusion
activity (Song et al. 2007). At least three types of mitochondrial proteases are known
to regulate Opa1 processing. Paraplegin, a subunit of the ATP-dependent m-AAA
protease; mitochondrial rhomboid protease (PARL), an orthologue of Pcp1 protease
that processes Opa1 orthologues Mgm1 and Yme1; and i-AAA protease (Duvezin-
Caubet et al. 2007; Song et al. 2007).
However, detailed characterization of Opa1 isoforms in other model organisms has
been absent. Recently, regulation of Opa1 processing in mouse tissues has been
published. Akepati et al. showed that in mouse OPA1 (mOPA1) gene exon 4 is not
involved in alternative splicing resulting in four different splice variants. Further
processing of Opa1 variants leads to a tissue-specific abundance of six isoforms
(figure 3.5; Akepati et al. 2008).
Figure 3.5: Structure of mouse Opa1 protein. Opa1 protein is imported into the
mitochondria via MTS that is cleaved by MPP protease (denoted by the arrow)
forming two long Opa1 isoforms. Domains 4b and 5b are encoded by exons 4b and
5b involved in alternative splicing. CC, coiled-coil domains; MPP, mitochondrial
processing peptidase; MTS, matrix-targeting signal; TM, transmembrane domain;
(modified from Akepati et al. 2008).
Loss of mitochondrial membrane potential (∆ψm) and ATP production due to
mitochondrial dysfunction induces fast proteolytic processing of long to short Opa1
isoforms that leads to mitochondrial fragmentation and segregation of dysfunctional
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mitochondria from the intact mitochondrial network. All Opa1 isoforms during the
proteolytic conversion remain in mitochondria and are not release into the cytosol.
The shift in the pattern of Opa1 isoforms was observed in patients and various model
systems of human disorders associated with mitochondrial dysfunction (MERRF,
MELAS, mtDNA depletion syndrome; Duvezin-Caubet et al. 2006).
3.3.2 Opa1 functions in cell
It has been already mentioned that Opa1 plays a key role in mitochondrial dynamics,
but its precise function is not known and it is not clear how can mutated Opa1 impair
mitochondrial function in cells. Olichon et al. showed that down-regulation of
Opa1 in HeLa cells leads to fragmentation of the mitochondrial network due to
fusion-fission imbalance, complete disorganization of the cristea, extreme sensitivity
to endogenous apoptosis induction and dissipation of mitochondrial membrane
potential (Olichon et  al. 2003). Most of the mutations in OPA1 gene cause
premature truncation of the protein that leads to loss of the coiled-coil C-terminal
domain and thus alteration of the GTPase activity which is necessary for the
mitochondrial fusion (figure 3.5). Fibroblasts from patients with Opa1 mutation
show fragmented mitochondrial network and decreased amount of Opa1 compared
to the controls (Olichon et al. 2007; Zanna et al. 2008).
Recently, Zanna et al. have shown that Opa1 protein interacts with some respiratory
complexes and apoptosis inducing factors (AIF) and thus reduced expression of
Opa1 associates with significant impairment of oxidative phosphorylation, mostly at
the level of complex I (Zanna et al. 2008).
3.3.3 Opa1 mouse models
In 2007, two groups have generated mouse models carrying mutations that are close
to reported human mutations that cause ADOA.
Davies et al. have used nonsense mutation (1051C>T) in exon 8 of OPA1 gene that
results in truncation (Gln 285 to Stop: Q285X) of the protein immediately prior to
the dynamin-related GTPase domain (Davies et al. 2007). Alavi et al. have reported
a mouse model carrying a splice site mutation (c.1065+5G>A) that skips exon 10
and leads to an in-frame deletion in the GTPase domain of Opa1 protein (Alavi et al.
2007).
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Both Opa1 mouse models display early embryonic lethality in the homozygous state.
Heterozygous OPA1 WT/ mut mice show ~50% reduction in amount of Opa1 protein
compared  to  controls  that,  in  this  state,  is  proposed  to  lead  to  haploinsufficiency.
Moreover, they found increased fragmentation of the mitochondrial network in cells
from OPA1WT/mut mice, optic nerve abnormalities (reduced number of axons, unusual
shape of the remaining axons and mitochondria with disorganized cristea) and mild
deficits in visual acuities that increased with age (Alavi et al. 2007; Davies et al.
2007). The Opa1 protein is essential in mammalian development and
haploinsufficiency is the main disease mechanism. These conclusions are consistent
with findings in human patients with ADOA (Davies et al. 2007).
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3.4 Autophagy/mitophagy
The essential aspect of cell physiology is the maintenance of cellular homeostasis
within the environmental stress conditions. Part of this maintenance involves
regulation and modification of biosynthetic and degradation pathways. In eukaryotic
cells are two main protein degradation routes where lysosomes present the end point
of degradation. In the first route, extracellular material is delivered to lysosomes by
pinocytosis, phagocytosis and receptor-mediated endocytosis. In the second one,
intracellular components are achieved by macroautophagy, microautophagy or
chaperon-mediated autophagy (Dunn 1994).
3.4.1 Macroautophagy
Macroautophagy, usually referred to as autophagy, is responsible for the bulk
degradation, typically activated by fasting and nutrient deprivation, and is necessary
for generating amino acids, fueling the Krebs cycle and maintaining the ATP
production (Kim et al. 2007).  Moreover,  it  is  thought to be important for the turn-
over of whole organelles and long-lived proteins at a steady state level of a cell
(Edinger and Thompson 2003; Mizushima et al. 2004).  In  contrast,  it  has  been
suggested that autophagy is associated with neurodegenerative diseases, cancer and
programmed cell death during embryogenesis (Edinger and Thompson 2003;
Mizushima et al. 2004).
In general, the autophagy mechanism initiates from a single-membrane structure,
also called isolation membrane or phagophore that encloses portion of cytoplasm
and organelles, resulting in formation of a double-membrane spherical
autophagosome. Then, the outer membrane of the autophagosome fuses with the
lysosome and the sequestered content is degraded together with the autophagosomal
inner membrane, also called autophagic body, by lysosomal hydrolases. This
degrading structure is termed autolysosome/ autophagolysosome and its lifetime is
short compared to other organelles (figure 3.6; Yoshimori 2004).
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Figure 3.6: Model for autophagy. The basic mechanism is the sequestration of the
cargo material by autophagosomes that lately fuse with lysosome/vacuole where
autophagic body is consumed together with the cargo (van der Vaart et al. 2008).
So far, 31 gene products, encoded by autophagy-related (ATG) genes, have been
identified to be required for the autophagic process in yeasts. However, the exact
molecular function of most of them is unclear. Identification of their mammalian
homologues suggests that molecular mechanisms of autophagy have been conserved
in all eukaryotes (Klionsky et al. 2003). Most of these proteins (Atg3, Atg5, Atg7,
Atg10, Atg12 and LC3) are involved in two ubiquitylation-like conjugation
modifications of target proteins which function in formation of autophagosomes.
(1) The Atg12-conjugation where Atg12 is attached to Atg5 is essential for the
formation of pre-autophagosomes. Atg7, an E1-like enzyme, activates Atg12 which
is transferred to Atg10, en E2-like enzyme, and conjugated to Atg5 to form an
autophagosomal precursor. (2) LC3-modification where phosphatidylethanolamine
(PE) is covalently linked to LC3, is essential for autophagosome formation
(Mizushima et al. 2004; Tanida et al. 2004).
3.4.2 Microtubule-associated protein 1 light chain 3
(Map-LC3)
Microtubule-associate protein 1 (Map) light chain 3 beta (LC3) is essential for
autophagy and widely use for its monitoring. In humans, three genes encode
homologous LC3 proteins: MAP1LC3A, MAP1LC3B and MAP1LC3C, two of which
(LC3A and LC3B) are conserved in mice (He et al. 2003). Like the LC3, a yeast
orthologue Atg8 exists in two modified forms and plays a critical role in formation
of autophagosomes in yeasts (Kabeya et al. 2000). After synthesis, Map1-LC3
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(or ProLC3) is cleaved by cystein proteases generating a soluble LC3-I in cytosolic
fraction and exposing its C-terminal glycine for further ubiquitylation-like reactions.
Subpopulation of LC3-I is also activated by Atg7, transferred to Atg3, a second
E2-like enzyme, and converted to LC3-II (Tanida et al. 2004). LC3-II is conjugated
with PE and bound tightly to autophagosome and autolysosome membranes (figure
3.7). LC3 expression and following conversion are greatly enhanced under
starvation conditions that induce autophagy. Thus, the number of autophagosomes
correlates with the amount of LC3-II. When autophagosomes fuse with lysosomes,
intra-autophagosomal LC3-II is degraded by lysosomal hydrolytic enzymes (figure
3.7; Kabeya et al. 2000; Kabeya et al. 2004).
Figure 3.7: Schematic diagram of autophagosome formation in mammalian
cells. A protein Apg5-complex in membrane of phagophore includes Apg5, Apg12
and Apg16L. It recruits LC3-II to the outer and inner membranes when the
elongation of membranes is initiated. The Apg5-complex leaves the membrane just
before or after membrane fusion, while LC3 remains (Yoshimori 2004).
Two more protein families have been identified as mammalian homologues of Atg8.
γ-aminobutyric-acid-type-A (GABAA)-receptor-associated protein (GABARAP)
and Golgi-associated ATPase enhancer of 16 kDa (GATE-16) also exist in form-II
(PE-conjugated) and localize with LC3-positive autophagosomes induced by
starvation. However, their precise role during autophagy is unknown (Kabeya et al.
2004).
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3.4.2.1 LC3 mouse models
Transgenic mice systematically expressing LC3 fused with green fluorescent protein
(GFP) and the method to monitor autophagy in mouse have been generated in 2004.
Mizushima et al. have revealed five patterns of starvation that differ between organs.
In the first group, autophagy is increasingly induced during the 48-starvation
(e.g. heart, slow-twitching muscles); in the second group, the autophagy is
significantly increased during the first 24-h starvation and then sustained (e.g. fast-
twitching muscles, podocytes). In the third group, the autophagy is induced in the
first 24-h starvation but reduced to basal level in the next 24-h (e.g. pancreas, liver).
In the fourth group, the autophagy is constitutively active (e.g. thymic epithelial
cells) in contrast to the fifth group where autophagy is not induced even after 48-h
starvation (e.g. brain). The induction of autophagy is an organ specific process that
does not always respond to nutrient starvation but might be more complex and
involved in other regulations, for example in T-cell development (Mizushima et al.
2004).
Knockout mouse model of LC3β, a protein encoded by MAP1LC3B gene, has been
generated by Cann et al. in 2008. Mice do not display compensatory increase in
LC3α. Furthermore, their findings in starved LC3β -/- MEFs showed that LC3β is
not required for the induction of autophagosomes under starvation conditions.
Mouse can develop normally in the absence of LC3βI and II due to compensation by
other ATG proteins (Cann et al. 2008).
3.4.3 Mitophagy
In general, autophagy is thought to be non-selective process. However,
autophagosomes containing protein aggregates or specific organelles, such as
endoplasmic reticulum, peroxisomes or mitochondria have been described. Thus,
subgrouping the autophagy into selective and nonselective types has been defined;
specific and exclusive elimination of structure as selective autophagy, whereas non-
selective autophagy is when different components are eliminated randomly (van der
Vaart et al. 2008).
Term mitophagy has been suggested to selective mitochondrial autophagy, though
mechanisms targeting mitochondria for mitophagy are not well understood. Under
normal conditions of living cells it has been demonstrated that autophagocytosed
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mitochondria are characterized by three features. (1) Reduced membrane potential
(∆ψm) of isolated non-fusing mitochondria that are produced by mitochondrial
fission from intact mitochondrial network, (2) reduced Opa1 levels and (3) reduction
of size. These mitochondria have reduced fusion capacity and are unlikely to be
recovered by fusion into polarized network even before being targeted by autophagy
(Twig et al. 2008). Mitochondrial dynamics where fusion triggers fission that is
essential for autophagy, functions as a quality control mechanism that reins
mitochondrial turnover (Twig et al. 2008).
In contrast, in hepatocytes during nutrient deprivation, mitochondrial fission occurs
coordinately with autophagosomes formation. Moreover, phagophores or pre-
autophagosomes go on to sequester completely the individual mitochondria which
depolarize in about 10 min after ring closure. As mitochondria inside of
autophagosomes or more specifically mitophagosomes depolarize, acidification
occurs and sequestered content is degraded (Kim et al. 2007).
It has been previously proposed that mitochondrial permeability transition (MPT)
represents a signal for targeting dysfunctional mitochondria to autophagic
degradation during nutrient deprivation. In the MPT, opening of permeable
transition (PT) pores in the mitochondrial inner membrane causes swelling that leads
to depolarization and rupture of the outer membrane and release of cytochrome c
into the cytosol (Elmore et al. 2001).
Recently, two new proteins involved in autophagic degradation have been found in
yeasts. Uth1p, the protein initially identified in regulation of yeast lifespan, is mainly
localized in mitochondrial outer membrane and is involved in the recognition of
mitochondria by the autophagic machinery induced by rapamycin or nitrogen
starvation (Kissova et al. 2004). Aup1p, encoded by YCR079w, is a yeast
mitochondrial protein phosphatase homologue that localizes in the mitochondrial
intermembrane space. This protein takes part in signal transduction mechanism that
marks mitochondria for selective degradation through mitophagy in stationary phase
yeast cells (Tal et al. 2007).
3.4.4 Mitochondrial protein acetylation on lysine residues
Dynamic post-translation modifications, such as a protein acetylation on lysine
residues, play crucial role in regulation of many cellular processes including
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DNA-protein interactions, subcellular localization, transcriptional activity and
protein stability. Proteomic survey revealed 277 unique acetylation sites in 133 of
mitochondrial proteins derived from both fed and fasted mouse liver mitochondria.
This amount corresponds to ≈ 20% of all mitochondrial proteins (Kim et al. 2006).
Yeast silent information regulator 2 (Sir2) and its homologues belong to the Sirtuin
family conserved from bacteria to humans (Onyango et al. 2002). This family of
NAD+-dependent protein deacetylase/mono-ADP-ribosyl-transferase enzymes
regulates gene silencing, aging, energy metabolism and mediates the effect of caloric
restriction on lifespan extension in several organisms (Lin et al. 2002). In mammals,
seven homologues (Sirt1-7) have been identified; three Sirtuins (Sirt1, Sirt6 and
Sirt7)  are  localized  to  the  nucleus;  Sirt2  is  the  only  one  present  in  cytoplasm,  and
three  Sirtuins  (Sirt3,  Sirt4  and  Sirt5)  reside  in  the  mitochondria  (Haigis  and
Guarente 2006).
3.4.4.1 Sirt3
Sirt3 is the first sirtuin identified in mitochondria (Onyango et al. 2002), however,
its localization and function has been keenly discussed. Schwer et al. in 2002 have
reported  human  Sirt3  (hSirt3)  full-length  protein  of  43  kDa  that  is  localized  to
mitochondrial matrix and is activated by cleavage of 142-AA from N-terminus
(Schwer et al. 2002). In contrary, Scher et al. have proposed that full-length hSirt3
completely resides in nucleus and translocates to mitochondria under cellular stress,
such as overexpression or apoptotic signals, where is localized in its processed form
(Scher et al. 2007). Moreover, utilizing immunofluorescence microscopy, Cooper
and Spelbrink have showed that hSirt3 is exclusive mitochondrial deacetylase
(Cooper and Spelbrink 2008).
Discrepancies in localization of Sirt3 are not only the case of the human homologue.
In 2005, Shi et al. have reported that murine Sirt3, preferentially expressed in brown
adipose tissue, lacks N-terminal region corresponding to 142-AA residues of hSirt3
protein and is localized on the inner mitochondrial membrane (Shi et al. 2005).
Recently, in agreement with their previous findings, Nakamura et al. have
determined that murine Sirt3 resides in the inner mitochondrial membrane, but its
localization is changed from mitochondria to nucleus when is co-expressed with
Sirt5 (Nakamura et al. 2008). On the contrary, endogenous Sirt3 has been showed as
soluble mitochondrial protein in mouse liver under both basal and stress conditions
38
(Lombard et al. 2007). In addition, they have generated SIRT3 knockout mice that
exhibit increase mitochondrial lysine acetylation compared to SIRT4 and SIRT5
knockout mice. Surprisingly, Sirt3-defficient mice are healthy and do not reveal
morphological or metabolical alterations under starvation condition or cold exposure
(Lombard et al. 2007).
Taken together, Sirt3 is thought to be a major mitochondrial deacetylase, but its
exact function in cellular processes is not well known. Sirt3 shows regulation of
mitochondrial functions. Its constitutive expression reduces membrane potential,
decreases production of ROS and increases oxygen consumption (Shi et al. 2005). In
2006, two papers have demonstrated that reversible acetylation of acetyl-CoA
synthetase 2 (AceCS2) modulated by Sirt3 in mitochondria, plays important role in
acetate conversion for energy production under ketogenic conditions (Hallows et al.
2006; Schwer et al. 2006). Recently, two new enzymes have been identified to be
deacetylated and thereby activated by human Sirt3: glutamate dehydrogenase
(GDH), a central metabolic regulator in mitochondrial matrix, and isocitrate
dehydrogenase 2, a key regulator in the tricarboxylic acid cycle (Schlicker et al.
2008).
3.4.4.2 Sirt4 and Sirt5
Sirt4 is also mitochondrial protein from Sirtuin family that resides in mitochondrial
matrix, but lacks deacetylase activity. Sirt4 exhibits ADP-ribosyltransferase activity
and is implicated in regulating amino acid-stimulation of insulin secretion in mice
pancreatic β-cell by inhibition of GDH (Haigis et al. 2006).
Sirt5 is the least characterized protein from mitochondrial Sirtuins. Its substrates and
functions in mammalian cells are largely unknown. Recently, Sirt5 has been
localized to mitochondrial intermembrane space where deacetylates cytochrome c.
However, it can translocate to mitochondrial matrix to play a role in communication
between nucleus and mitochondria as Sirt3 translocates to nucleus when
co-expressed with Sirt5 (Nakamura et al. 2008; Schlicker et al. 2008).
Sirt4- and Sirt5-deficient mice are healthy, fertile and do not exhibit increase
mitochondrial protein hyperacetylation (Lombard et al. 2007).
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3.5 Mitochondrial diseases
The mitochondrial diseases encompass a wide variety of multisystematic disorders
with various combinations of clinical features that usually affect brain and muscle,
probably because of their highest energetic requirements. Mitochondria are under
the control of two genomes: mitochondrial, where 37 genes are directly or indirectly
involved in OXPHOS, and nuclear that encodes all proteins operating in
mitochondria. Genetic defects can occur in both genomes, thus mitochondrial
disorders can be inherited by maternal or Mendelian trait or combination of the two.
3.5.1 Mutations in mtDNA causing mitochondrial disorders
The main features of mitochondrial diseases proceed from peculiar mitochondrial
genetics that strikingly differ from nuclear. In general, mitochondria with all copies
of mtDNA in cells are transmitted through the maternal line. Thus, homoplasmic
mtDNA mutations are transmitted to all maternal offspring. In case of heteroplasmic
mutations, the amount of mutant mtDNA differs between tissues and the threshold
effect appears only with the high amount of mutant mtDNA molecules. Mutations of
mtDNA can be divided in two groups: (1) inherited point mutations and
(2) large-scale rearrangements (i.e. partial deletions and duplications).
3.5.1.1 Inherited point mutations in mtDNA
More than 200 point mutations may be homoplasmic or heteroplasmic and are
usually maternally inherited (www.mitomap.org).  Pathological mutations that arise
in protein-enconding genes, affect specifically function of particular OXPHOS
complex, while mutations in RNA genes impair the overall mitochondrial protein
synthesis.   Patients develop wide variety of clinical  symptoms where abnormalities
in central nervous system are frequently associated with mitochondrial myopathy.
Most of the mutations in genes encoding complex I subunits have been associated
with Leber hereditary optic neuropathy (LHON) characterized by acute or subacute
loss of vision that usually affects males in early adulthood (Wallace et al. 1988).
NARP, the neurogenic muscle weakness, ataxia and retinis pigmentosa is associated
with mutations in MT-ATP6 gene  (Holt et al. 1990) and clinical features clearly
correlate with the level of heteroplasmy. Furthermore, MELAS, a mitochondrial
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encephalomyopathy with lactic acidosis and stroke-like episodes, is associated with
the most frequent heteroplasmic point mutation in the tRNALeu (3243A>G, Goto et
al. 1990) and MERRF, a myoclonic epilepsy with ragged-red fibers (RRF) where
transition 8344A>G in the tRNALys gene is the most common pathological mutation
(Wallace et al. 1988, reviewed by McKenzie et al. 2004; Zeviani and Di Donato
2004).
3.5.1.2 MtDNA rearrangements
Over 100 large-scale mtDNA rearrangements including single large deletions or
deletions conjugated with structurally related duplications, are always heteroplasmic
(www.mitomap.org). A threshold level for rearranged molecules lacking a part of
the mitochondrial genome, is 40 - 60% that is enough for OXPHOS failure. Three
main diseases are associated with these mutations. CPEO, Chronic Progressive
External Ophthalmoplegia is characterized with late-onset of ophthalmoplegia,
proximal myopathy and exercise intolerance. Kearns-Sayre Syndrome (KSS) is
usually sporadic disorder with the onset before age of 20 years, characterized by
CPEO and pigmentary retinopathy, with additional features of cerebellar ataxia,
cardiac conduction block and diabetes mellitus (Zeviani et al. 1988). Finally,
Pearson Marrow-Pancreas Syndrome (PS) is a rare but usually fatal disorder
involving hematopoetic system with severe exocrine pancreatic insufficiency (Rotig
et al. 1990). Deletions can be found in muscle and blood in the comparable amount.
However, multiple deletions of mtDNA are usually caused by defects in nDNA
genes of mtDNA maintenance leading to subsequent intergenomic signaling
impairment (reviewed by McKenzie et al. 2004; Zeviani and Di Donato 2004).
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3.5.2 Instability of mtDNA caused by nDNA defects
3.5.2.1 Autosomal dominant progressive external ophthalmoplegia (adPEO)
Autosomal  dominant  PEO  is  a  common  mitochondrial  disorder  associated  with
multiple mtDNA deletions that belongs to the subgroup of human mitochondrial
diseases caused by mutations in nuclear genes. The main clinical features of PEO
patients include progressive weakness of extraocular muscles that limits the eye
movements and general exercise intolerance. The disease onsets in the adulthood,
the first  signs arise in the range from 20 to 40 years of age.  Muscle biopsies show
the presence of RRF due to subsarcolemmal accumulation of abnormal
mitochondria. The diagnosis depends on the detection of multiple mtDNA deletions
in the skeletal muscle (Zeviani et al. 1989). Additional features are variable among
families and may include sensory ataxia, motor peripheral neuropathy, cataracts,
hearing loss, hypogonadism, parkinsonism, severe depression or avoidant
personality (Suomalainen et al. 1997, reviewed by Spinazzola and Zeviani 2005).
A secondary accumulation of large mtDNA deletions results from a primary defects
in nDNA genes. Recently, the fifth gene that encodes Opa1 protein was attached to
the group of four responsible genes: POLG1, POLG2, PEO1 and SLC25A4 (Amati-
Bonneau et al. 2008; Hudson et al. 2008).
In 2000, the SLC25A4 gene encoding Ant1 became the first gene linked to adPEO
with multiple deletions, when Kaukonen et al. found one heterozygous missense
mutation A114P and one sporadic mutation V289M, both in the transmembrane
domain (Kaukonen et al. 2000). Phenotype of Ant1-PEO patients is relatively mild
with slowly progressive myopathy and little extramuscular symptoms. Lately, new
mutations, in particular T293C in Greek family and A90D mutation in German
family have been found in adPEO families (Deschauer et al. 2005).
The mutations in PEO1 gene that encodes Twinkle helicase protein are responsible
for approximately 30% of the adPEO cases (Lamantea et al. 2002). The primarily
identified missense mutations (i.e. A475P, A359T, W474C, W315L) and
heterozygous 13 amino acids duplication (dup352-364) are localized in the linker
region  or  in  the  helicase  domain  (figure  3.8).  However,  the  impairment  of
hexamerization due to mutations in the linker region was not observed (Spelbrink et
al. 2001). Lately, several new mutations in Twinkle in patients with adPEO, such as
S369Y (Lewis et al. 2002), R303W (Agostino et al. 2003) or F370L (Jeppesen et al.
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2008) have been described. Recently, using the molecular three-dimensional
structure model of Twinkle has demonstrated that Twinkle with the pathogenic
mutations (I367T and R374Q) in the linker region cannot form hexamers or unwind
the duplex DNA due to lack of ATPase  activity (Korhonen et al. 2008).
Figure 3.8: Schematic representation of mutations in Twinkle. The mutations
in the linker were used to generate the transgenic Twinkle mice and the
corresponding human mutations are linked to cause adPEO.
The dup352-364 mutation of PEO patient that affects the linker region of Twinkle
protein has the most severe described phenotype of Twinkle-PEO patients
(Spelbrink et  al. 2001). They show multisystemic disorder with severe retarded
depression. MtDNA deletions are detected in the skeletal muscle, brain and heart.
The activities of respiratory chain enzymes show remarkable reduction in the
skeletal muscle and brain. The various abnormalities in the mitochondria are
observed in electron microscope in all tested tissues (Suomalainen et al. 1997).
The third gene, in which mutations are linked to adPEO, is POLG1 encoding the
catalytic subunit of mitochondrial Polγ. Dominant mutations are responsible for 45%
of adPEO cases that have more complicated clinical phenotypes than those of
Twinkle-PEO cases (Lamantea et al. 2002). The first heterozygous mutation
(Y955C) was identified in the Belgium family diagnosed with symptoms of PEO,
muscle weakness and multiple mtDNA deletions with RRF found in muscle biopsies
(Van Goethem et al. 2001). To date, all autosomal dominant mutations in POLG1
causing PEO (with one exception) are located in the polymerase domain of the
enzyme, i.e. Y955C mutation leads to loss of polymerase activity and decrease in
processivity of Polγ (Graziewicz et al. 2004). However, most of the mutations found
in POLG1 gene are associated with autosomal recessive PEO (arPEO) and patients
are usually presented as compound heterozygotes with two arPEO alleles.
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POLG2 gene encoding the accessory subunit of Polγ is the fourth gene where
heterozygous dominant mutation causes adPEO with multiple mtDNA deletions
(Longley et al. 2006). Mutated protein can not bind with the catalytic subunit and
fails to stimulate progressive DNA synthesis. This leads to stalling of the Polγ in the
replication fork and producing mtDNA deletions that cause COX deficiency in
muscle fibers (Longley et al. 2006).
3.5.2.2 Other phenotypes caused by mutations in Twinkle
Infantile onset spinocerebellar ataxia (IOSCA, OMIM 271245), a typical example of
the Finnish disease heritage, is caused by recessive mutations in the PEO1 gene.
This severe neurodegenerative disorder manifests at the age of 9-18 months as
ataxia, muscle hypotonia and loss of deep tendon reflexes. Morphological
characterization includes sensory axonal neuropathy and progressive neuropathy of
the cerebellum, brain stem and spinal cord (Koskinen et al. 1994). Two pathological
relevant mutations in PEO1 gene have been linked to IOSCA patients. Finnish
patients are either homozygotes for the founder missense substitution of an adenine
to guanine leading to an Y508C change or compound heterozygote having the
founder mutation and 1472C>T mutation affecting allelic expression level (Nikali et
al. 2005).  Interestingly,  PEO  patients  with  dominant  Twinkle  mutations  are
characterized by presence of multiple mtDNA deletions in the skeletal muscle,
whereas IOSCA patients with recessive mutations do not show any signs of mtDNA
defects but harbor mtDNA depletion in the brain and liver. Thus, IOSCA have
become a member of mtDNA depletion syndromes (Hakonen et al. 2008).
MtDNA depletion syndrome (MDS) is a highly heterogeneous group of disorders
associated with recessive mutations in nuclear genes of mtDNA maintenance
proteins or dNTP metabolism enzymes. Clinically, they include hepatocerebral and
myopathic forms of diseases, genetically characterized by a reduction in mtDNA
copy number (Moraes et al. 1991). MDS associated genes include for example TK2,
DGUOK, POLG1, SUCLA2 or TP (reviewed by Sarzi et al. 2007). Recently,
recessive pathological mutations in the Twinkle protein leading to MDS have been
reported, two compound hetorozygotes for Y508C and A318T mutations (Hakonen
et al. 2007) and two homozygous patients for T457I mutation (Sarzi et al. 2007).
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3.5.2.3 Mutations in the OPA1 gene causing ADOA
Autosomal dominant optic atrophy (ADOA, OMIM 165500) is non-syndromic
mitochondrial hereditary optic neuropathy (http://lbbma.univ-angers.fr/eOPA1/).
This disease usually begins before 10 years of age with moderate-to-severe loss of
visual acuity, optic nerve pallor, abnormalities in color vision and centocoecal
scotoma. Retinal ganglion cell degeneration has been suggested as
a main cause that leads to atrophy of the optic nerve (Delettre et al. 2002).
Four gene loci have been linked to cause ADOA and other optic atrophies: OPA1
(3q28-29), OPA3 (19q13.2-13.3), OPA4 (18q12.2-12.3) and OPA5 (22q12.1-q13)
(Olichon et  al. 2007). Mutations, predominantly described in OPA1 gene, include
substitutions,  deletions  or  insertions  and  are  spread  over  the  coding  region  of  the
gene, but their functional consequences in ADOA patients are not well understood.
The R455H mutation of Opa1 that alters GTPase domain has been found to be
involved in ADOA and moderate progressive deafness (ADOAD; Amati-Bonneau et
al. 2005). Reduction of mtDNA copy number has been found in patients with
ADOA associated with mutations in OPA1 gene (Kim et al. 2005).
In  2008,  two  new  cases  of  ADOA  associated  with  multiple  mtDNA  deletions  in
skeletal  muscle  have  been  described.  Hudson  et  al.  have  presented  family  with
bilateral visual failure and optic atrophy of childhood onset, following by
ophthalmoplegia, a combination of cerebellar and sensory ataxia in adulthood and
hearing impairment. Affected respiratory chain complex I and mosaic defect of
complex IV (COX) have been identified in a muscle homogenate or muscle fibers.
Multiple mtDNA deletions have been detected in patient skeletal muscle.
Sequencing of entire mitochondrial genome has revealed a previously unreported
nucleotide transition in MT-ATP6 gene (Hudson et al. 2008).
Amati-Bonneau et al. have reported new symptomatic form of optic atrophy with
sensorineural deafness, cerebellar ataxia, axonal sensory-motor polyneuropathy and
mitochondrial myopathy with RRF and COX negative fibers. The OPA1 ´plus´
symptoms, frequently complicated by CPEO and accumulation of multiple mtDNA
deletions in the skeletal muscle, are caused by five dominant missense point
mutations changing amino acids in Opa1 GTPase domain (Amati-Bonneau et al.
2008).
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3.6 The transgenic Twinkle mice
3.6.1 Twinkle transgene and generating of mice
Transgenic Twinkle mice have been generated in the laboratory of Prof. Anu
Suomalainen (Tyynismaa et al. 2005). The mutation corresponding to the in-frame
39-bp duplication at nucleotides 1053-1092 (c.1053_1092dup) of the human PEO1
gen causing adPEO in patients, was used to create transgenic mouse with
a duplication of amino acids 353-365 (dup353-365, figure 3.8) in mouse Twinkle
protein and referred to as the Deletor mice (Twinkledup). The transition 1075G>A in
the human PEO1 gene, was designed to create transgenic mice with substitution of
threonine for alanine at amino acid position 360 (A360T, figure 3.8) in mouse
Twinkle protein and referred to as the AT mice (TwinkleAT). Using pHBApr-1-neo
with mouse Twinkle cDNA + intron 4 have allowed the expression of full-length
Twinkle as well as its splice variant Twinky under β-actin promoter. The final DNA
constructs were linearized with BglII and NdeI  and after the purification they were
injected to mouse fertilized oocytes by pro-nuclear microinjection. From pseudo-
pregnant carrier females were obtained four founder mice (C, D, E, F mouse lines)
expressing dup353-365 mutation that corresponds to dup352-364 mutation of PEO
patients and three founder mice (G, H, I mouse lines) with A360T mutation that
corresponds to A359T PEO patient mutation (Spelbrink et al. 2001). The transgenic
mice developed normally, had a normal lifespan and could reproduce. Mice from F1
generation were bred to produce F2 homozygous mice that also had normal lifespan
and development.
3.6.2 Characterization of the transgenic Twinkle mice
First signs of mitochondrial myopathy were noted at the age of 12 months in the
Deletor skeletal muscle (figure 3.9). Histochemical analysis has shown COX
negative (COX-) muscle fibers without increased SDH staining (SDH+), indicating
dysfunction of respiratory chain without increased mitochondrial proliferation.
Skeletal muscle of 18-month-old Deletor has shown COX-/SDH+ fibers (figure 3.9).
All these findings correspond with the relative age of onset with human disease
when related to the expected lifespan (Suomalainen et al. 1997). No changes in the
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amount of COX-/SDH+ fibers in the Deletor heart muscle compared to wild type
controls have been detected.
Figure 3.9: Histochemical double staining of the skeletal muscle. The muscle
fibers with normal COX activity are stained light and dark brown (wild type 12 and
18 months). The COX deficient (COX-) muscle fibres are not stained and remain
white as shown in 12-month-old Deletor sample. The accumulation of mitochondria
is  shown  by  excessive  SDH  activity  (SDH+,  blue)  in  affected  muscle  of  the
18-month-old Deletor. Scale bars: 50 µm (modified from Tyynismaa et al. 2005).
Histochemical analysis of 18-month-old Deletor brain has shown COX -/SDH+ in
≈1% of Purkinje cells in the cerebellum; most of large pyramidal neurons and those
of indusium griseum in the cerebrum. A few COX-/SDH+ neurons were identified
from the olfactory bulbs, substantia nigra and the hypothalamus. MtDNA depletion
or accumulation of mtDNA deletions could cause the COX deficiency in these
neurons. Findings of COX deficiency in Purkinje cells of the transgenic mice or in
humans have not been previously described but their loss has been noted in patients
with mtDNA maintenance defects (Van Goethem et al. 2004).
The features of mild muscle phenotype with only few COX- fibers  present  in  AT
mice were consistent with PEO patients carrying the same missense mutation.
A359T human patient develop late-onset PEO at ≈ 50 years with moderate
myopathy and no CNS involvement (Spelbrink et al. 2001).
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Interestingly, only mildly decreased or low normal activities of respiratory chain
complexes I, III and IV that contain mtDNA-encoded subunits were shown in
affected muscles (Tyynismaa et al. 2005). In line with these findings, the transcript
analysis has revealed impaired energy metabolism and signs of starvation in the
Deletor muscle. Thus, a respiratory chain deficiency leads the cell to catabolism:
activation of autophagy and utilization of structural proteins (Tyynismaa, personal
comunication).
Furthermore, electron microscopy of the Deletor mildly affected muscle fibers has
exhibited enlarged mitochondria and their increased number in subsarcolemmal
region (figure 3.10). The cristea structures in these mitochondria have been
recognizable compared to the severely affected fibers where large mitochondria had
concentric cristae, resembling onion-like structures and electron-dense inclusions.
Mitochondria found in autophagosomes point to autophagic degradation, called
mitophagy (figure 3.10).
Figure 3.10: Electron microscopy pictures of the Deletor skeletal muscle. A, the
muscle section shows a normal fiber (NF) with a highly organized structure and
a defective fiber (DF) with an abnormal mitochondria. B, autophagosomes with
sequestered mitochondria (indicated by arrow). C, the enlarged mitochondria in
subsarcolemmal region of a muscle fiber. The left arrow points to an inclusion inside
an enlarged mitochondria and the right arrow to onion-ring like cristae (modified
from Tyynismaa et al. 2005).
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Accumulation of multiple mtDNA deletions is main feature of patients with
Twinkle-PEO mutations. The 3-kb “minimal mtDNA molecules” consisted of 12S
rRNA, 16S rRNA and the D-loop region were amplified from muscle of the Deletor
mice (figure 3.11). However, amplification of mtDNA from brain has revealed
molecules from full-length to ≈3 kb in size (figure 3.11). DNA sequence analysis
has revealed similar deletion hotspots in the muscle and brain suggesting that these
sites form major deletions in transgenic Twinkle mice. The quantification of mtDNA
copy number in the Deletor mouse tissues has revealed mtDNA depletion only in the
brain.  MtDNA level  as  well  as  somatic  mtDNA point  mutation  load  in  the  Deletor
muscle samples was similar to those of the non-transgenic controls.
Figure 3.11: Multiple mtDNA deletions in the Deletor skeletal muscle and
brain. The 3-kb “minimal mtDNA molecules” in the muscle are pointed by the thick
arrow, whereas the full length mtDNA molecules by the thin arrow. The range of
deleted mtDNA molecules in the brain is also indicated (modified from Tyynismaa
et al. 2005).
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4. Materials and Methods
4.1 Animals
This  work  was  approved  by  the  University  of  Helsinki,  animal  care  committee
(Helsinki, Finland), and all experiments were done in accordance with good practice
of handling laboratory animals.
Transgenic animals of inbred strains FVB/N and BALB/c utilized in this work were
generated in the laboratory of Prof. Anu Suomalainen (Tyynismaa et al. 2005) and
referred to as the Deletor mice (C – F mouse lines). For the mtDNA deletions assays
the liver, kidney, testis and intestine from the Deletor males and females mice aged
15 – 17 months were tested. The skeletal muscle, brain, liver and heart samples from
mice aged 22 – 26 months were collected and used for tissue homogenates or
mitochondrial enrichment isolation.
Transgenic  animals  referred  to  as  the  AT  mice  (G  –  I  mouse  lines)  were  also
generated in the laboratory of Prof. Anu Suomalainen (Tyynismaa et al. 2005). The
skeletal muscle and brain samples from males and females mice aged 15 – 17
months were tested for mtDNA deletions.
Wild type Twinkle overexpressor (A and B mouse lines), generated in the laboratory
of Prof. Anu Suomalainen (Tyynismaa et al. 2004) were used to set up the method
of DNA walking.
Deletor littermate mice with normal Twinkle genotype were used as wild type
negative control. In each assay, animals at the same age as the Deletor or AT mouse
littermates were tested.
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4.2 Equipment
Centrifuges:
Centrifuge 5804R (Eppendorf, Germany)
Centrifuge Allegra 25R (Beckman Coulter, Inc., Germany)
PCR cycler:
PTC-200 (MJ Research, Biorad, USA)
Scanner:
Typhoon 9400 scanner (Amersham Biosciences, USA)
Freezer:
Thermo model 720 (-80 °C) (Thermo Electron Corporation, USA)
Electrolux Intuition (-20 °C)
Spectrophotometer:
UV-2401 PC (Shimadzu)
Nanodrop (ND-1000, NanoDrop Technologies, Inc,USA)
Western blotting equipment:
Glasses, tanks and plastic equipment (BioRad)
Semi-dry blotter:
Semiphor transphor unit (Amersham Biosciencies, USA)
Light Microscope:
Axioplan 2 Universal Microscope (Zeiss)
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4.3 Buffers and solutions
Buffer used for DNA isolation
DNA isolation buffer – 200 ml:
5 ml 20 % SDS (MP biomedicals, LLC)
4 ml 5 M NaCl (Sigma)
10 ml 1 M Tris-HCl pH 8.1 (Sigma)
8 ml 0.5 M EDTA (Sigma)
Buffers for mitochondria isolation and sucrose gradient
HIM buffer – 500 ml:
200 mM mannitol (Sigma)
70 mM sucrose (Sigma)
10 mM HEPES (Sigma)
1 mM EGTA (Sigma)
pH 7.5 with KOH
1 M / 1.5 M sucrose – 2.2 ml each:
1 M / 1.5 M sucrose (Sigma)
10 mM HEPES pH 7.4 (Sigma)
10 mM EDTA (Sigma)
PBS – phosphate-buffered saline 1x
+  protease inhibitors (PBS+, Roche)
Buffer used for tissue homogenates
RIPA buffer:
0.75 M NaCl (Sigma)
5 % NP40 (Sigma)
2.5 % sodium deoxycholate (Sigma)
0.5 % SDS (MP biomedicals, LLC)
0.25 M Tris-HCl pH 8.0 (Sigma)
10 mM DTT (Sigma)
protease inhibitors
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Loading buffer for SDS-PAGE -10 ml:
1.5 ml 1 M Tris-HCl pH 6.8
600 μl 20% SDS (MP biomedicals, LLC)
3 ml glycerol (Sigma)
1.5 ml β-merkaptoethanol (Sigma)
0.0018 g bromphenol blue
Buffers used for Blue-Native PAGE (BN-PAGE)
3x Gel Buffer (3xGB) – 100 ml:
(1.5 M aminocaproic acid, 150 mM Bis-tris , pH 7.0)
19.68 g aminocaproic acid (Sigma)
3.14 g Bis-Tris (Sigma)
MB2 buffer:
0.5 ml 3x GB
0.5 ml 2 M aminocaproic acid (13.12g /50 ml) (Sigma)
4 μl 500 mM EDTA (Sigma)
SBG – sample buffer – 10 ml:
(750 mM aminocaproic acid, 5 % Serva Blue G)
3.75 ml 2 M aminocaproic acid (13.12g /50 ml) (Sigma)
0.5 g Serva Blue G (Serva)
Solutions used for Coomassie Blue staining
Coomassie Fix solution:
50 % methanol (Fluka)
10 % acetic acid (Fluka)
Coomassie Blue solution – 1 l:
2 g Serva Blue (Serva)
75 ml glacial acetic acid (Fluka)
500 ml ethanol (Fluka)
Coomassie Blue distain solution:
450 ml methanol (Fluka)
100 ml acetic acid (Fluka)
400 ml H2O
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Solution used for Complex I activity assay
1 mM stock NADH (Roche)
Complex I activity solution – 20 ml:
4 ml 1mM NADH (Roche)
16 ml 0.1 mM Tris-HCl  pH 7.4 (Sigma)
20 mg nitrotetrazolium blue chloride (Sigma)
Buffers used for COX/ SDH staining
0.05 M phosphate buffer:
Buffer A: 1.3799 g NaH2PO4 x H2O (Sigma)
      50 ml H2O
Buffer B: 1.4196 g Na2HPO4 (Sigma)
      50 ml H2O
9.5 ml of buffer A, 40.5 ml of buffer B and H2O were mixed to final volume 150 ml.
pH 7.4 was determined and H2O was added to get 200 ml of final volume.
COX-incubation buffer:
9 ml 0.05 M phosphate buffer
5 mg DAB (Sigma)
20 mg catalase (Sigma)
10 mg cytochrome c (Sigma)
750 mg sucrose (Sigma)
SDH-incubation buffer:
10 ml 0.05 M phosphate buffer
10 mg Nitro blue tetrazolium (Sigma)
50 mg sodium succinate (Fluka)
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Table 4.1: Solutions for prepration SDS-PAGE
Solutions Stacking gel Separating gel
4 % 10 % 12 % 15 %
H2O 6.1 ml 4.0 ml 3.4 ml 2.4 ml
0.5 M/1.5  M Tris-HCl 2.5 ml 2.5 ml 2.5 ml 2.5 ml
30 % acrylamid 1.3 ml 3.4 ml 4.0 ml 5.0 ml
20 % SDS  50 μl 50 μl 50 μl 50 μl
10 % APS 50 μl 50 μl 50 μl 50 μl
TEMED 5 μl 5 μl 5 μl 5 μl
5x running buffer – 1 l:
15 g Tris-HCl pH 8.3 (Sigma)
72 g Glycine (Sigma)
3 g SDS (MP biomedicals, LLC)
1x transfer buffer – 1 l:
2.213 g CAPS (Sigma)
100 ml methanol (Fluka)
pH 11 with NaOH
1x TBS-T – 1 l:
2.42 g Tris (Sigma)
8.0 g NaCl (Sigma)
1 ml Tween 20 (Amresco)
1x Towbin buffer – 1 l:
3.03 g Tris (Sigma)
14.41 g Glycine (Sigma)
0.5 g SDS (MP biomedicals, LLC)
200 ml methanol (Fluka)
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4.4 Antibodies and enzymes
4.4.1 Antibodies
Table 4.2: The antibodies used for SDS-PAGE and BN-PAGE
Primary antibodies
Name
Animal
source
Clonality Company
anti-LC3B rabbit  polyclonal Novus Biologicals
anti-OPA1 mouse monoclonal BD Transduction laboratories
anti-actin I-19 goat polyclonal Santa Cruz Biotechnology,Inc
anti-acetylated-
lysine
rabbit polyclonal Cell Signaling Technology
anti-C-II-70 kDa mouse monoclonal Mitosciences
anti-NDUFA9 mouse monoclonal Mitosciences
Secondary antibodies
anti-rabbit goat monoclonal Molecular Probes
anti-mouse goat monoclonal Molecular Probes
anti-goat goat monoclonal Calbiochem
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4.4.2 Enzymes
DNA Polymerase:
High-Fidelity DNA polymerase Phusion (Finnzymes)
Dynazyme II DNA polymerase (Finnzymes)
Expand Long Template PCR system (Roche)
Ligase:
T4 DNA ligase (Clontech)
Restriction enzymes:
Dra I (Clontech)
EcoR V (Clontech)
Pvu II (Clontech)
Stu I (Clontech)
4.4.3 Molecular Markers
               (Roche)                             (Roche)                   (New England Biolabs)
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4.5 Methods:
4.5.1 Isolation of DNA from mouse tissues
DNA was extracted from snap frozen mouse tissue samples. Liver, testis, kidney and
intestine from Deletor male and female mice and skeletal muscle and brain from AT
male and female mice were allowed to melt on ice, homogenized with scalpel and
then incubated with 0.4 mg Proteinase K (20 mg/ml, Sigma-Aldrich) and 700 µl of
DNA isolation buffer in +55 ºC shaker over night. Then 700 µl of phenol (Amresco)
was added to tubes and samples were centrifuged at 2 500 rpm for 5 min at +4 ºC.
Aqueous upper-phases were collected and addition of phenol was repeated.
Aqueous upper-phases were collected to new tubes where 700 µl of choloroform-
isoamylalcohol (24:1, Fluka) was added and samples were centrifuged at 2 500 rpm
for  5  min  at  +4  ºC.  DNAs  were  purified  with  1  300  µl  of  ice-cold  99  %  EtOH
(Fluka)  and  130  µl  of  7.5  M ammoniumacetate  (Sigma)  and  stored  in  -20  ºC over
night.  Samples  were  then  centrifuged  at  13  000  rpm  for  30  min  at  +4  ºC,
supernatants were removed and pellets were purified in 500 µl ice-cold 70 % EtOH.
After centrifugation at 13 000 rpm for 15 min at +4 ºC, supernatants were removed
and DNA pellets were dissolved in 70 µl of TE-buffer (pH 7.5). DNA concentrations
were measured by the NanoDrop spectrophotometer at 260 nm.
4.5.2 DNA Walking
4.5.2.1 Construction of DNA libraries
The Genome Walker Universal Kit (Clontech) was used to identify the exact
position of the Twinkle transgene in genome of the wild-type Twinkle overexpresor
(A) and the Deletor (C) mouse lines.
The Genome Walker libraries that contained un-cloned, adaptor-ligated genomic
DNA fragments were prepared. To form Genome Walker libraries, 2.5 µg of
genomic DNA from the A and C mouse lines were digested with 80 U of four
different  restriction  enzymes  (Dra  I,  EcoR  V,  Pvu  II  and  Stu  I,  Clontech)  with
specific digestion buffers in 100 µl of reaction volume at +37 °C over night
(16-18h). To each library, 95 µl of phenol (Amresco) was added and span briefly at
room temperature. Aqueous upper-phases were collected to new tubes and mixed
with 95 µl of chloroform (Fluka).  After separation of phases by brief spin at  room
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temperature, aqueous upper-phases were transferred and DNAs were purified by
190 µl of ice-cold 95 % EtOH (Fluka), 25 µl of NH2Ac (7.5 M) and 2 µl of glycogen
(10 µg/ µl, Sigma). Samples were centrifuged at 14 000 rpm for 15 min at +4 °C,
supernatants were removed and pellets were washed in 100 µl of ice-cold 80 %
EtOH (Fluka). After centrifugation at 14 000 rpm for 10 min at +4 °C, the final
pellets  were  dissolved  in  20  µl  of  TE-buffer  (10/0.1,  pH  7.5).  To  determine  the
approximate quantity of purified DNA, 1 µl from each reaction tube was removed,
mixed with 5x BPB + glycerol and ran on a 0.6 % agarose + EtBr (20 µg/ 50ml) gel
along the 1 kb DNA Ladder (New England Biolabs). From each reaction tube, 4 µl
of digested, purified DNA was transferred to new tubes and incubated with 1.9 µl of
Genome  Walker  adaptors  (25  µM)  and  3  U  of  T4  DNA  ligase  (6  U/µl,  Clontech)
with 10x Ligation Buffer in 8 µl of reaction volume at +16 °C over night. To hold
the constant temperature, PCR cycler was used and the reaction was then stopped by
increased temperature up to +70 °C for 5 min. Finally, 72 µl of TE-buffer (10/1, pH
7.5) were added to each tube.
4.5.2.2 PCR-based DNA walking
The genome libraries were used to polymerase chain reaction (PCR)-based DNA
walking. The Genome Walker adaptor primers (AP) and nested primers designed to
the  3´  end  of  the  Twinkle  transgene  (Tw,  figure  4.1  and  table  4.3)  were  used  to
amplify the DNA fragments from each library.
Figure 4.1: The Twinkle transgene and position of nested primers. In the
construct, the Twinkle gene is expressed under the β-actin promoter and two primers
with direction of DNA amplification are shown in color. Bgl, Hpa and Nde are
restriction sites used for transgene construction. Tw, Twinkle.
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Table 4.3: Primers for PCR-based DNA walking and sequencing reaction.
Name Sequence
Tw1 5´- GTGAAAACCTCTGACACATGCAGCTC - 3´
Tw2 5´- GGAGACGGTCACAGCTTGTCTTGTAAG - 3´
AP1 5´- GTAATACGACTCACTATAGGGC - 3´
AP2 5´- ACTATAGGGCACGCGTGGT - 3´
T7 forward 5´- TAATACGACTCACTATAGGG - 3´
M13 reverse 5´- CAGGAAACAGCTATGAC - 3´
The primary PCR was performed in 50 µl of final volume containing 1 U of High-
Fidelity  DNA polymerase  Phusion  (2  U/  µl,  Finnzymes)  with  HF Buffer,  1  µM of
both  primers  AP1 and  Tw1 (table  4.3),  0.2  mM of  dNTPs  and  1  µl  of  each  DNA
library. The initial step at 98 °C for 30 sec was followed by 7 cycles with 98 °C for
10 sec and 72 °C for 30 min. Subsequent 32 cycles consisted of 98 °C for 10 sec,
67 °C for 3 min with the final extension 67 °C for 7 min. The primary PCR products
(5  µl)  with  5x  BPB  +  glycerol  were  analyzed  on  a  1.5  %  agarose  +  EtBr  (20  µg/
50 ml) gel along 1 kb DNA Ladder (New England Biolabs).
In new tubes, 1 µl of each primary PCR was diluted into 49 µl of deionized water.
The secondary PCR was performed in 50 µl of reaction volume containing 1 U of
High-Fidelity DNA polymerase Phusion (2 U/ µl, Finnzymes) with HF Buffer, 1 µM
of  both  primers  AP2  and  Tw2  (table  4.3),  0.2  mM  of  dNTPs  and  1  µl  of  diluted
primary PCR products. The initial step at 98 °C for 30 sec was followed by 5 cycles
with 98 °C for 10 sec and 72 °C for 30 min. Subsequent 20 cycles consisted of 98 °C
for 10 sec, 67 °C for 3 min with the final extension 67 °C for 7 min. The secondary
PCR  products  (5  µl)  with  5x  BPB  +  glycerol  were  analyzed  on  a  1.5  %  agarose
+ EtBr (20 µg/ 50 ml) gel along 1 kb DNA Ladder (New England Biolabs).
The strongest bands that presented the final products were purified from agarose gels
using QIAquick Spin Gel Extraction Kit (Qiagen), cloned into pCR-Blunt II-TOPO
(Invitrogen) according to manufacturer’s instructions and sequenced with vector T7
forward and M13 reverse primers (table 4.3). Sequences were matched to the mouse
genome through BLAST searches of NCBI Mouse Genome Resources
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
60
4.5.2.3 Verification of the transgene integration site
The integration of the transgene to the identified genomic position was verified by
PCR amplification using gw-primers (table 4.4). The PCR was performed in
25 µl of reaction volume containing 0.2 mM of dNTPs, 2 mM of MgCl2,  1 µM of
each  primer,  1  U  of  Dynazyme  II  DNA  polymerase  (Finnzymes)  with  10x  Buffer
and 25 ng of mouse genomic DNA. The initial step of the PCR program at 95 °C for
2 min was followed by 35 cycles of 95 °C for 1 min, 60 °C for 10 min and 72 °C for
30 min with the final extension at 72 °C for 10 min. The length of PCR product was
350 bp for A mouse line.
Table 4.4: Primers for verification and genotyping PCR.
Name Sequence
gw-twinkle3F 5´- GCTTGTCTGTAAGCGGATGC - 3´
gw-chr5R 5´- GGCATCAGACATGTAGGCAGT - 3´
mTw1549F 5´- TGCAGTTCATGATGGGTCAC - 3´
mTw1719R 5´- TGCTGTCTGCAGTTCCTTGT - 3´
The results were then compared to results from genotyping PCR of five transgenic
mice  and  five  controls.  The  genotyping  was  based  on  amplification  of  the
endogenous Twinkle and the transgene that was shorter due to lacking of intron 3.
The PCR products of transgene and endogenous Twinkle were 161 bp and 339 bp
long,  respectively.  The  amplification  of  50  ng  of  genomic  DNA  was  done  using
0.5 µM of both mTw1549F and mTw1719R primers (table 4.4) and performed in
25 µl of reaction volume containing 0.6 U of Dynazyme II DNA polymerase
(Finnzymes)  with  10x  buffer,  0.2  mM  of  dNTPs  and  2  mM  of  MgCl2. The initial
step at 95 °C for 4 min was followed by 35 cycles of 95 °C for 1 min, 56 °C for
1 min and 72 °C for 1 min with the final extension at 72 °C for 10 min. On 1 %
agarose + EtBr (20 µg/ 50ml) gel, 10 µl of both Genome Walker and genotyping
PCR products were run along the Marker V (DNA Molecular Weight Marker V,
8-587 bp, Roche). The gels were scanned on Typhoon 9400 scanner (Amersham
Biosciences).
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4.5.3 Long PCR of mtDNA
Long PCR was used for the detection of mtDNA deletions. The specific primers
were designed to amplify different sizes of mtDNA molecules (table 4.5).
Table 4.5: MtDNA primers for long PCR.
Name Sequence
mmtDNA-longF 5´- GAGGTGATGTTTTTGGTAAACAGGCGGCGGGGT - 3´
mmtDNA-longR 5´- GGTTCGTTTGTTCAACGATTAAAGTCCTACGTG - 3´
The PCR was performed in buffer 2 with 3.8 U of the Expand Long Template PCR
system  (Roche),  0.2  mM  of  dNTPs  and  1  µM  of  both  mmtDNA-longF  and
mmtDNA-longR primers in 50 µl of final reaction volume. The same PCR program
was used for all tissue samples. The initial step at 92 ºC for 2 min was followed by
30 cycles at 92 ºC for 10 sec and annealing temperature 68 ºC for 12 min with the
final extension at 68 ºC for 7 min. On 1% agarose + EtBr (20 µg/ 50 ml) gel, 5 µl of
each PCR products with 5x BPB + glycerol were separated along the Marker II
(DNA Molecular Weight Marker II, 0.12 – 23.1 kbp, Roche). Full-length mtDNA
ran  as  upper  band  around  16  kbp  and  mtDNA  deletions  were  presented  as  lower
 3 – 10 kbp bands.
4.5.4 Mouse tissue sections and COX / SDH staining
Mouse intestine samples were collected and frozen by isopentane freezing method.
Cryostat  sections  of  12  µm  were  separately  or  simultaneously  stained  with
cytochrome c oxidase (COX) and succinate dehydrogenase (SDH). Frozen sections
on glass plates were incubated in COX-incubation solution for 30 min at room
temperature in moist chamber. After three washes in water, plates were incubated in
SDH-incubation solution for 30 min at +37 °C in moist chamber. After three washes
in water, plates were dehydrated in ascending alcohols (70 %, 94 % and three times
in 100 %), cleared three times in xylene and mounted with xylene based DePeX
mounting medium (Gurr, BDH). Stained sections were analyzed by light microscope
(Axioplan 2 Universal Microscope, Zeiss).
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4.5.5 Tissue homogenates
Fresh mouse tissue samples were homogenized in RIPA buffer. The samples were
incubated on ice for 20 min and centrifuged at 13 000 x g for 5 min at +4 °C.
Supernatants were collected and stored in -80 °C.
4.5.6 Enrichment of mitochondria
Fresh mouse tissue samples were homogenized with a teflon pestle in 5 ml of ice-
cold HIM buffer and centrifuged at 600 x g for 20 min at +4 °C. Supernatants were
collected and centrifuged at 10 000 x g for 10 min at +4 °C. Supernatants were then
removed and pellets were resuspended in 2 ml of ice-cold HIM buffer. After the
centrifugation at 10 000 x g for 10 min at +4 °C the final pellets were resuspended in
1x PBS+. Protein concentration was measured by the Bradford method (Bradford
1976) according to manufacturer’s instructions (Bio-rad Laboratories, Inc.) using
spectrophotometer.
4.5.7 Pure mitochondrial isolation using sucrose gradient
Fresh mouse tissue samples were collected and mitochondrial pellets were prepared
by using the enrichment protocol. Pellets were resuspended in 400 µl of ice-cold
HIM. Pure mitochondria were isolated by using sucrose gradient prepared by filling
the  centrifuge  tubes  with  2.2  ml  of  upper  1  M sucrose  and  2.2  ml  of  lower  1.5  M
sucrose  solutions.  Samples  were  centrifuged  at  18  800  rpm  for  1  h  at  +4  °C,  the
mitochondrial layers were collected, resolved in 1 ml of ice-cold HIM buffer and
centrifuged at 12 000 rpm for 5 min at +4°C. The final pellets were resuspended in
200 µl of PBS+.
4.5.8 SDS-PAGE and Western Blotting
Proteins samples (10-40 μg) were mixed with loading buffer 1:1, denaturated at
95 °C for 5 min and loaded into the gel. Discontinuous gels consisting of 4 % upper
stacking gel (pH 6.8, table 4.1) and lower resolving or separating gel (pH 8.8, table
4.1) of particular concentration were prepared according to the specific protein
properties (table 4.6). Electroblotting method was used to transfer proteins onto
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PVDF membranes (Immobilon-FL, Millipore). Membranes were blocked at room
temperature on a shaker and probed with specific primary antibody at +4 ºC over
night and then with secondary antibody at room temperature for 1h (table 4.2). After
incubation with the primary and secondary antibody, membranes were washed three
times for 5 min in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and
signals were detected by ECL Plus Western Blotting Detection System (GE
Healthcare) using Typhoon 9400 scanner (Amersham Biosciences) or by LumiGLO
(LumiGLO Reagent and Peroxide, Cell Signaling Technology) on X-OMAT LS
(Kodak) film. BenchMark Prestained Marker (Invitrogen) was used to estimate the
protein sizes.
Table 4.6: Characteristics of conditions for specific proteins.
Tissue homogenates
Protein
Separat-
ing gel
Blocking Primary antibody
LC3 15%
5% milk
(TBS-T)
anti-LC3B (1:3000 dilution in
5% BSA (TBS-T))
OPA1 10%
5% milk
(TBS-T)
anti-OPA1 (1:1000 dilution in
5% milk (TBS-T))
β-actin
1% BSA
(TBS-T)
anti-actin I-19 (1:2000 dilution in
5% milk (TBS-T))
Mitochondria enrichment
Acetylation
on Lysine
12%
5% milk
(TBS-T)
anti-acetylated-lysine (1:1000
dilution in 5% BSA (TBS-T))
Complex II
5% milk
(TBS-T)
anti-C-II-70 kDa (1:10 000 dilution
in 5% milk (TBS-T))
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4.5.9 Mitochondrial samples for Blue native electrophoresis
(BN-PAGE)
Fresh mouse tissue samples were used to prepare mitochondrial enrichment pellets
for blue native electrophoresis. Concentrations of mitochondrial proteins that were
resuspended in PBS+ were measured by the Bradford method (Bradford 1976)
according to manufacturer’s instructions (Bio-rad Laboratories, Inc.) using
spectrophotometer and the samples were diluted to final concentration of 5 µg/µl
with PBS+. Equal volumes of freshly prepared digitonin solution (4 mg/ml) to
permeabilize cell membranes were added into the samples and incubated on ice for
5 min. Tubes were then filled up with PBS+ and centrifuged at 10 000 x g for 10
min at +4 °C, supernatants were removed and pellets were resuspended in MB2
buffer. 1/10 volume of 10 % lauryl maltoside (0.1 g/ml) was added to the samples,
incubated on ice for 15 min and centrifuged at 20 000 x g for 20 min at +4 °C.
Supernatants were collected and stored at -80 °C. Protein concentration was
measured by the Bradford method (Bradford 1976) according to manufacturer’s
instructions (Bio-rad Laboratories, Inc.) using spectrophotometer.
4.5.10 Preparation of Blue native gel and electrophoresis
Blue native gels consisting of 4 % upper stacking gel and lower gradient gel
prepared  from 6  % and  15  % separating  gel  mixture  were  set  up  for  separation  of
mitochondrial proteins from the skeletal muscle and brain. The protein samples were
mixed with SBG - sample buffer and loaded on gel at 20 µg of total proteins. The
Peptide Marker Kit (Amersham Biosciences) was used to evaluate the protein sizes.
Proteins were transferred to PVDF membranes (Immobilon-FL, Millipore) by using
semi-dry western blotting method (6 mA, 1.5 h). Membranes were blocked in 5 %
milk (TBS-T) for 1h at room temperature and then probed with primary antibody for
Complex I subunit NDUFA9 (1:500 dilution in 5 % BSA (TBS-T), table 4.2) at
+4 °C over night. Then probed with secondary goat anti-mouse antibody (1:1000
dilution in 5 % milk (TBS-T), table 4.2). After incubation with secondary antibody,
membranes were washed three times for 5 min in TBS-T and signals were detected
by  ECL  Plus  Western  Blotting  Detection  System  (GE  Healthcare)  using  Typhoon
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9400 scanner (Amersham Biosciences) or by LumiGLO (LumiGLO Reagent and
Peroxide, Cell Signaling Technology) on X-OMAT LS (Kodak) film.
Immediately after electrophoretic separation of mito proteins, the Blue Native gels
were incubated in Coomassie Fix solution for 20 min at room temperature and then
stained  with  Coomassie  Blue  solution  over  night  at  room  temperature.  After  the
staining, gels were washed tree times in Coomassie Blue destaining solution for 20
min and dried.
Immediately after electrophoresis, the Blue Native gels of separated mito proteins
were used for in-gel Complex I activity assay. Gels were incubated in 10 ml of
1  mM  NADH  solution  for  10  min  at  room  temperature  and  then  with  Complex  I
activity solution for 10 min at room temperature. Gels were washed in water over
night and dried.
4.5.11 Statistical analysis
Signals were quantified by ImageQuant TL software (Amersham Biosciences) and
statistical analysis was calculated with Student t-test using Microsoft Excel software
that gave two-tailed P-values.
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5. Results
5.1 Identification of the transgene integration site
5.1.1 Result of the BLAST search
Since the integration of transgene construct to nDNA is a random process, the
knowledge of exact position in the mouse genome is required for the subtle Deletor
characterization. The PCR-based Genome Walker kit was used to amplify PCR
products that contained genomic sequence flanking the transgene integration site.
The products were purified from the agarose gels, cloned into the sequencing vectors
and sequenced. The sequences were matched to the mouse genome through BLAST
searches of NCBI Mouse Genome Resources. The Twinkle transgene in the
A mouse line was identified in band E1 on chromosome 5 in the intron 3 of
TMPRSS11d gene (Transmembrane protease serine 11D; OTTMUSG00000028240).
In the C mouse line the transgene was found in non-coding band A1 on chromosome
16.
Figure  5.1:  Integration  sites  of  Twinkle  transgene  in  A  and  C  mouse  lines.
Particular integration sites on mouse chromosome 5 (band E1) and 16 (band A1) are
indicated by arrows (modified from www.ensembl.com).
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5.1.2 Verification of the transgene integration site
The genomic position of the Twinkle transgene in the A mouse line was verified by
specific PCR by comparison to the mouse genotyping PCR. PCR products of five
transgenic and five control mouse samples were separated on 1 % agarose gel + EtBr
along the Marker V (figure 5.2). Specific PCR product validating the correct
genomic position of the Twinkle transgene on chromosome 5 in the A mouse line
was 350 bp (indicated by the arrow, figure 5.2). Transgene and endogenous Twinkle
PCR products were 161 bp and 339 bp long, respectively (indicated by the arrows).
In wild type samples PCR products of chromosome 5 as well as transgene Twinkle
were missing. The genomic position of the Twinkle transgene in the C mouse line
was verified using the same PCR method (data not shown).
Figure 5.2: Twinkle transgene integrated on chromosome 5 in the A mouse line.
PCR products from verification of the transgene integration site separated on
agarose gel. A, A mouse line samples; Wt, wild type; V, Marker V.
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5.2 MtDNA deletions in different tissues
5.2.1 Analysis of the Deletor mouse tissues
In the previous studies, the expression level of Twinkle transgene in particular
tissues was examined and mtDNA deletions were found in the Deletor skeletal
muscle and brain (Tyynismaa et al. 2005). Thus, additional tissues such as kidney,
liver, testis and intestine of the Deletor male and female mice were tested. MtDNA
was amplified by long PCR and the PCR products were analyzed on 1% agarose gels
with EtBr (figure 5.3). The DNAs isolated from the skeletal muscle of wild type and
the Deletor mice were used as negative and positive controls, respectively. The full-
length mtDNA was successfully amplified in all tested samples, but prominent
mtDNA deletions were found only in the skeletal muscle. Furthermore, no
differences between males and females were observed. The shorter bands of
mtDNA,  detected  in  some  tissue  samples  (i.e.  in  the  kidney  of  the  Deletor  female
sample), represented the mtDNA deletions whose amount does not reach the
minimal critical level to manifest as disease phenotype in the particular tissue.
Figure  5.3:  No  mtDNA  deletions  in  the  Deletor  mouse  tissues  other  than  the
skeletal muscle. The full-length mtDNA (indicated by the arrow) was amplified in
all tested tissue samples. MtDNA deletions of multiple sizes are indicated by the
vertical line. DEL, Deletor; WT, wild type; II, DNA marker II; N, negative control;
P, positive control.
69
5.2.2 Analysis of the AT mouse tissues
To further characterize the AT mice, mtDNA deletions detection assay in the
skeletal muscle and brain of male and female mice was performed. MtDNA was
amplified  by  long  PCR  and  the  PCR  products  were  analyzed  on  1%  agarose  gels
with EtBr (figure 5.4). The DNAs isolated from the skeletal muscle of wild type and
the Deletor mice were used as negative and positive controls, respectively. No
prominent mtDNA deletions were found in the AT mouse tissue samples.
Figure  5.4:  No  mtDNA  deletions  in  AT  mouse  tissues  samples. The full-length
mtDNA (indicated by the arrow) was amplified in all tested tissue samples. MtDNA
deletions of multiple sizes are indicated by the vertical line.  AT, A360T; WT, wild
type;  II,  DNA  marker  II;  N,  negative  control  –  DNA  from  the  wild  type  skeletal
muscle; P, positive control – DNA from the Deletor skeletal muscle.
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5.3 COX/ SDH histochemistry of the Deletor mouse tissue
The secondary defects in mtDNA caused by mutations in nuclear genes of mtDNA
maintenance proteins are usually manifested in post-mitotic tissues with the highest
energetic needs. Whether these defects can be observed also in proliferative tissue,
the mouse intestine tissue was analyzed for COX and SDH activity. The frozen
intestine sections of the Deletor and wild type mice were separately or
simultaneously stained for COX and/or SDH and analyzed by light microscope
(figure 5.5). Histochemistry of intestine mucosa showed normal COX activity
(COX+,  dark brown) and SDH activity (SDH+, dark blue) in colonic crypts (figure
5.5). Either the white crypts indicating absence of COX activity (COX -) or the bright
blue crypts strongly stained with SDH indicating mitochondrial accumulation were
not observed.
Figure 5.5: No COX-/SDH+ colonic crypts in the Deletor intestine. COX/ SDH
histochemistry of the skeletal muscle. Double staining for COX/ SDH activities of
the wild type (A) and Deletor (B) mouse tissue samples. Single staining for COX
activity and for SDH activity of the wild type (C, E) and Deletor (D, F) mouse tissue
samples, respectively. Scale bars: 50 µm.
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5.4 Opa1 detection and mitochondrial fragmentation
5.4.1 Opa1 in different Deletor tissues
The shift in the pattern of Opa1 isoforms has been observed in several mouse models
of human disorders characterized by mitochondrial dysfunction. To study Opa1 in
the 24-month-old Deletor, the mouse brain, heart and liver homogenates with the
wild type mouse counterparts were separated on 10 % resolving gel and the proteins
were probed with monoclonal mouse anti-OPA1 antibody. β-actin was used as
a loading control. Opa1 isoforms migrated as a mixture of at least five bands within
the range of 80-100 kDa (figure 5.6). The particular bands that represented either the
long isoforms (L1-, L2-OPA1) or the short isoforms (S3-, S4-, S5-OPA1) could not
be distinguished for individual quantification, thus all long isoforms (L-OPA1) as
well as S4 and S5-OPA1 from short isoforms (S-OPA1) were quantified as a single
upper and lower band using Student t-test, respectively, and normalized against
β-actin signal. Only S3-OPA1 could be quantified as a single band in all tested
samples (figure 5.6). Significant increase was found in the level of S-OPA1 isoforms
in the Deletor brain compared to the wild type tissue samples, p = 0.003 (figure 5.7
A). No clear shift to a specific isoform was seen in these tissues.
Figure 5.6: Significant increase of S-OPA1 in the 24-month-old Deletor brain.
The immunodetection of Opa1 isoforms in the brain, heart and liver homogenates
separated by SDS-PAGE. DEL, Deletor; WT, wild type.
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Figure 5.7: Significant increase of S-OPA1 in the 24-month-old Deletor brain.
A, the quantification of Opa1 isoforms in the brain tissue (n = 3). Significant
difference is indicated by the asterisk (p = 0,003). B, the quantification of Opa1
isoforms in the heart  tissues (n = 3). C, the quantification of Opa1 isoforms in the
liver tissue (n = 3). The standard deviations (SDs) are indicated. WT, wild type.
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5.4.2 Opa1 in the Deletor skeletal muscle
In patients with mitochondrial diseases, the defects of mitochondrial functionality
(such as mitochondrial respiratory chain) and morphology are mainly presented in
the skeletal muscle.  Thus, the tissue homogenates of the Deletor skeletal muscle, as
a mouse model of adPEO, and the control mouse samples were separated on 10 %
resolving gel and the proteins were probed with monoclonal mouse anti-OPA1
antibody. β-actin was used as a loading control (figure 5.8 A). Five bands within the
range of 80-100 kDa were detected in all skeletal muscle samples, quantified
separately and normalized against β-actin signal (figure 5.8 B). All Opa1 isoforms
were slightly elevated and statistically significant increase was identified in the level
of L2-OPA1 isoform in the Deletor compared to wild type samples (n = 4, figure 5.8
B).
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Figure 5.8: Significant increase of L2-OPA1 isoform in the 24-month-old
Deletor skeletal muscle (n = 4).  A, the immunodetection of Opa1 isoforms in the
skeletal muscle samples separated by SDS-PAGE. B, the quantification of long and
short Opa1 isoforms. Significant difference is indicated by the asterick (p = 0.04).
The SDs are indicated. DEL, Deletor; WT, wild type.
B
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5.5 Coomassie Blue staining of OXPHOS complexes
The mitochondrial enrichments of the skeletal muscle and brain of the Deletor and
wild type mice were separated on Blue native electrophoresis and stained with
Coomassie Blue (figure 5.9). Complexes of oxidative phosphorylation system
(OXPHOS)  were  detected  in  their  native  form.  Complex  I,  II,  III  and  V  were
detected in both the skeletal muscle and the brain samples whereas complex IV was
detected only in the skeletal muscle, by this method. The Coomassie Blue analysis
showed discrepancies in Complex I in both Deletor tissues (figure 5.9).
Figure 5.9: Complexes of OXPHOS detected in the Deletor tissues. The
mitochondrial enrichments of the skeletal muscle and brain separated on Blue native
gel stained with Coomassie Blue. Main protein sizes of molecular marker are
indicated. DEL, Deletor; WT, wild type; M, Peptide marker.
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5.6 Blue native electrophoresis and in-gel activity of
Complex I in the Deletor skeletal muscle and brain
According to the findings from Coomassie blue staining in the skeletal muscle and
brain samples, the amount and activity of Complex I were analyzed by Blue native
electrophoresis of the Deletor compared to the non-transgenic mice. Proteins of
mitochondrial enrichments were separated on gradient 6 - 15 % resolving gel.
Complex I was detected by mouse monoclonal anti-NDUFA9 antibody, the activity
was shown after incubation with NADH substrate. Complex I was detected in both
tissues. Due to the isolation method, the Complex I in partly disrupted mitochondrial
membranes was represented as upper band. Neither in the skeletal muscle nor in the
brain  was  found  a  major  difference  in  the  amount  or  in  the  activity  of  Complex  I
(figure 5.10).
Figure 5.10: No  major  difference  in  amount  or  activity  of  Complex  I  in  the
24-month-old Deletor skeletal muscle and brain. The immunodetection of
Complex I and its in-gel activity in the skeletal muscle and brain samples separated
by BN-PAGE. DEL, Deletor; WT, wild type.
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5.7 Autophagy/mitophagy and detection of LC3
5.7.1 LC3 in the Deletor skeletal muscle
To confirm the findings of mitophagy observed by electron microscopy, the skeletal
muscle samples of the Deletor and wild type mice were separated on 15 % resolving
gel and the autophagy protein marker was detected by rabbit polyclonal anti-LC3B
antibody. β-actin was used as a loading control. Both LC3-I and LC3-II bands were
detected in all samples (figure 5.11 A). The bands were quantified and normalized
against β-actin signal. LC3-II was significantly increased in the Deletor skeletal
muscle compared to the wild type mouse samples (figure 5.11 B).
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Figure 5.11: The autophagy marker LC3-II is significantly increased in the
24-month-old Deletor skeletal muscle. A, the immunodetection of LC3 in skeletal
muscle homogenates separated by SDS-PAGE. LC3-I and LC3-II are indicated by
arrows. B, the quantification of LC3 in the skeletal muscle samples, LC3-I: p= 0.18;
LC3-II: p=0.0004 (n = 3). The SDs are indicated. DEL, Deletor; WT, wild type.
B
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5.7.2 LC3 in different Deletor tissues
Analyzing the role of autophagy in different human pathologies, tissue homogenates
from the brain, heart and liver of the Deletor and wild type mice were separated on
15 % resolving gel and probed with rabbit polyclonal anti-LC3B antibody. β-actin
was used as a loading control. Both forms of LC3 were detected as two separate
bands (figure 5.12 A). The bands were quantified separately and normalized against
β-actin signal. Neither the amount of LC3-I nor of LC3-II was significantly changed
in the tested samples (figure 5.13).
Figure 5.12: The autophagy marker LC3-II is not significantly increased in the
24-month-old Deletor brain, heart and liver. The immunodetection of LC3 in the
brain (A), heart (B) and liver (C) homogenates separated by SDS-PAGE. LC3-I and
LC3-II are indicated by the arrows. DEL, Deletor; WT, wild type.
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Figure 5.13: The autophagy marker LC3-II is not significantly increased in the
24-month-old Deletor brain, heart and liver (n = 3). The quantification of LC3 in
the brain (A), heart (B) and liver (C). The SDs are indicated. WT, wild type.
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5.8 Protein acetylation on Lysine residues
5.8.1 Pattern of acetylated proteins in different Deletor
tissues
To test the theory that protein acetylation might be a specific signal for
mitochondrial autophagy or degradation, the enriched fractions of mitochondria
from the skeletal muscle, brain and liver of the Deletor and wild type mice were
separated on 12 % resolving gel and acetylation was indicated by polyclonal rabbit
acetylated-lysine antibody. Complex II subunit 70 kDa was used as a loading control
(figure 5.14). Significant differences in the general pattern of mitochondrial protein
acetylation between the Deletor and wild type mouse tissue counterparts (n = 3)
were not found. However, a distinct difference was found in the pattern of
mitochondrial protein acetylation among different tissues (figure 5.14).
Figure 5.14: Different general pattern of mitochondrial protein acetylation
between the Deletor tissues. The enriched mitochondrial fractions from the skeletal
muscle, brain and liver samples separated by SDS-PAGE. Main protein sizes of the
molecular marker are indicated. DEL, Deletor; WT, wild type; C-II-70, complex II
subunit 70 kDa.
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5.8.2 Pattern of acetylated proteins in the Deletor brain tissue
The minimal differences in the acetylation pattern could not be distinguish in
mitochondrial enrichment, and therefore mitochondria were isolated from the brain
tissue using sucrose gradient and separated on 12 % resolving gel. Acetylation was
indicated by polyclonal rabbit acetylated-lysine antibody and complex II subunit
70 kDa was used as a loading control (figure 5.15). The Deletor and wild type brain
tissue did not show difference in the general pattern of acetylation of mitochondrial
proteins. However, changes in the abundance of individual bands of approximately
20 kDa and 35 kDa were revealed (indicated by arrows, figure 5.15).
Figure 5.15: No difference in the general pattern of mitochondrial protein
acetylation in the 24-month-old Deletor brain. Pure mitochondria from the
Deletor and wild type brain samples separated by SDS-PAGE. Main protein sizes of
the molecular marker are indicated. Differences in the individual bands are indicated
by arrows. DEL, Deletor; WT, wild type; C-II-70, complex II subunit 70kDa.
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6. Discussion
 Mitochondrial diseases are a large group of disorders with extremely heterogeneous
symptoms ranging from pure myopathy to multi-systemic involvement. They are
characterized by defects in both mitochondrial and nuclear genome, leading to
mitochondrial respiratory chain deficiency. Several mouse models for mitochondrial
dysfunction have been generated and studied for presymptomatic disease
progression or different therapeutic ideas. Since late-onset mitochondrial myopathy
has been one of the most common manifestations of mitochondrial diseases in
adulthood, the Deletor mouse with adPEO mutation in PEO1 gene is a valuable tool
for an understanding of mitochondrial pathogenesis.
6.1 Determination of Twinkle integration site in two
transgenic mouse lines
The knowledge of exact integration site is an important feature of the transgenic
mice, since the random insertion process to a coding sequence of any autosome can
impair a function and/or expression of the particular gene product at the insertion
site leading to false interpretation of the phenotype. Moreover, random incorporation
into the sex chromosomes can lead to gender differences.
DNA walking is a method useful for finding an integration site of a transgene in the
mouse genome, because it could be insert into any of 40 mouse chromosomes. In
general, the transgene construct is integrated in the form of concatemer,
a polymer of associated DNA fragments, which usually contains from one to ten
copies of the original fragment. Thus, a semi-quantitative Southern blot method was
utilized to determine the number of incorporated Twinkle constructs (Tyynismaa et
al. 2004). Four copies of wild type Twinkle construct were identified in the A mouse
line and three copies of dup352-364 Twinkle construct in the C mouse line. The
integration site of wild type Twinkle construct was found on chromosome 5 in the
intron  3  of TMPRSS11d gene (Transmembrane protease, serine 11D;
OTTMUSG00000028240) of the A mouse line. The further study of the
transmembrane serine protease impairment and its subsequent implications to mouse
phenotype is required, but these were not the aim of this study. The non-coding band
A1 on chromosome 16 was identified as the integration site in the Deletor C mouse
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line. In this case, the construct does not seem to have any further implications on the
Deletor phenotype.
6.2 MtDNA deletions are present in the Deletor skeletal
muscle
Twinkle-PEO patients are characterized by muscle weakness and exercise
intolerance with avoidant personality features frequently associated with multiple
deletions of mtDNA. Deleted mtDNA molecules accumulate in patients´ brain,
skeletal muscle and heart, but the highest expression of Twinkle in humans is in the
skeletal muscle and pancreas (Spelbrink et al. 2001). Previously, multiple mtDNA
deletions were showed in the Deletor skeletal muscle and brain, together with
Twinkle transgene expression in the skeletal muscle, brain, liver, heart and kidney
(Tyynismaa et al. 2005, personal comunication). In this study, the presence of
mtDNA deletions was examined in several Deletor tissues, in particular the skeletal
muscle, kidney, testis, liver and intestine. Apparent mtDNA deletions were detected
only in the Deletor skeletal muscle. This result corresponds with the findings from
PEO patients with dup352-364 mutation in the Twinkle protein and confirmed the
Deletor mouse as an accurate model for late-onset adPEO. Moreover, the result
might support the suggestion that different replication and/or reparing mechanisms
can operate in different tissues and thus, mtDNA deletions can arise only in several
ones (Goffart et  al. 2009).  No  mtDNA  deletions  were  observed  in  the  skeletal
muscle and brain of AT mice. Thus, these mice do not replicate the disease
phenotype and may not be useful in Twinkle-PEO studies.
6.3 No respiratory deficient crypt cells present in Deletor
intestine tissue
MtDNA mutations have been previously linked to limitation of mammalian lifespan.
A homozygous transgenic mice expressing mitochondrial Polγ with defective proof-
reading activity and referred to as “mutator mice”,  have shown accumulation of
somatic mtDNA point mutations that lead to respiratory chain dysfunction and
phenotype of premature aging (Trifunovic et al. 2004). Recently, an accelerated
accumulation of mtDNA deletions in the brain and heart has been described in these
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mice resulting from dysfunction of Polγ during replication (Vermulst et al. 2008).
Although, Twinkle together with Polγ are responsible for precise mtDNA
replication, the Deletor that accumulates mtDNA deletions in the skeletal muscle
and  brain,  did  not  show  either  the  increase  of  mtDNA  point  mutation  load  or
premature aging. These findings were obtained from post-mitotic mouse tissues
using  histochemical  staining  to  detect  loss  of  COX  activity  and  respiration
deficiency (Tyynismaa et al. 2005). To investigate whether dysfunctional Twinkle
can result in the respiratory deficient phenotype also in replicative cells, such as
colonic crypt stem cells, the histochemical analysis of the Deletor intestine was
proceeded. The advantage of studying the colonic tissue is that colonic crypt stem
cells  are  present  at  the  crypt  base  and  thus,  majority  of  cells  within  an  individual
colonic crypt are the progeny of a single stem cell. If mtDNA rearrangements
accumulated beyond a critical threshold in a stem cell, the whole crypt showed COX
deficiency (Taylor et al. 2003). Neither the COX/SDH staining of frozen sections of
the intestine from 24-month-old Deletor nor the long PCR analysis of mtDNA
showed significant differences in this tissue compared to the nontransgenic
littermate mice. The dup352-364 Twinkle mutation seems to affect the replication
mechanism  that  leads  to  accumulation  of  mtDNA  deletions  and  COX  deficiency
only in post-mitotic tissues but not in the proliferative cells. Hence, it might be
possible that in the replicative cell the dNTP pool in mitochondria is supplied better
by  dNTPs  from  cytosol  than  in  cell  of  post-mitotic  tissues  and  thus,  the  stalling
effect of mutant Twinkle can be exceeded. Recently, no mtDNA deletions have been
observed in cultured cells from adPEO patients, even though the clear
stalling/pausing of mutant Twinkle during mtDNA replication has been proved
(Goffart et al. 2009).
6.4 Slight changes in the pattern of Opa1 isoform in the
Deletor tissues
Mitochondria in cells form a dynamic reticulum that is maintained by a balance of
fusion and fission events and dysfunction of these processes can play a key role in
various diseases. Mitochondrial fusion is regulated through processing of protein
Opa1 depending on mitochondrial inner membrane potential (∆ψm; Ishihara et al.
2006). This dynamin-related GTPase anchored in the inner membrane, exists in
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L-OPA1 and S-OPA1 isoforms that both are likely important for Opa1 function in
mitochondrial fusion (Song et al. 2007). Mutations in OPA1 gene  are  known  to
cause autosomal dominant optic atrophy type 1 (ADOA) whose new form associated
with multiple mtDNA deletions in the skeletal muscle and fragmentation of
mitochondrial network has been recently reported (Amati-Bonneau et al. 2008;
Hudson et al. 2008). Beside ADOA patients, the mitochondrial fragmentation and
the shift in the pattern of Opa1 isoforms have been shown in various model systems
of human disorders associated with mitochondrial dysfunction, such as in fibroblasts
from “mutator mice” or in the heart tissue of Tfam knock-out mice (Duvezin-Caubet
et al. 2006). Furthermore, the analysis of the skeletal muscle from patients
diagnosed with respiratory chain defects, in particular with mtDNA depletion
syndrome or  MELAS,  has  shown this  shift  in  Opa1 isoforms compared  to  healthy
controls (Duvezin-Caubet et al. 2006).
Thus, one could expect that in the skeletal muscle of Deletor mice, a model for
mitochondrial myopathy with mtDNA deletions, the shift in the pattern of Opa1
isoforms will be clearly observed. Surprisingly, all detected Opa1 isoforms were
slightly elevated in the Deletor samples, compared to the wild type counterparts,
suggesting an enhanced turnover of mitochondrial fusion/fission machinery. The
significant increase was found in amount of L2-OPA1, the isoform that is processed
to S4- and S5-OPA1 isoforms and is sufficient to restore the mitochondrial fusion
and morphology and prevent the cells in culture from apoptosis (Frezza et al. 2006;
Song et al. 2007). Therefore, the higher level of L2-OPA1 in the Deletor skeletal
muscle may indicate the need of muscle fibres to protect against premature apoptosis
due to respiratory deficient mitochondria, leading to upregulation of mitophagy.
Moreover, in the case of Deletor, a significant shift in the pattern of Opa1 isoforms
to the short ones was detected in the brain samples, where in mouse tissue is present
an extremely high level of L2-OPA1 isoform (Akepati et al. 2008). The slight
increase of S-OPA1 isoform might reflect only a small amount of respiratory
deficient cells in the Deletor brain. In the heart and liver tissues the particular bands
of L-OPA1 and S-OPA1 isoforms were well resolved but not significantly increased
compare to the wild type counterparts.
Nevertheless, in the Deletor skeletal muscle and brain all respiratory chain
complexes were showed with no difference compared to the wild type tissues.
Neither the amount of complex I nor its in-gel activity was changed in tested tissues
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of  the  Deletor  and  wild  type  mice.  These  results  can  be  related  to  findings  from
fibroblasts of ADOA patients, where BN-PAGE did not show  significant difference
either,  but  the  amount  of  complex  I  was  slightly  increased  and  its  activity  was
slightly reduced (Zanna et al. 2008).
6.5 Mitophagy proved in the Deletor skeletal muscle
Autophagy is an ongoing process that, at basal conditions, is responsible for
degradation of structural proteins and damaged organelles. In cells, a functional and
an intact mitochondrial network is maintained by interplay between mitochondrial
fusion and fission leading to degradation of nonfunctional mitochondrial in process
called mitophagy. Under the starvation conditions, the salvaging function of
autophagy becomes important, especially in post-mitotic tissues.
In the case of Deletor skeletal muscle, the primary mutation in PEO1 gene causes
accumulation of mtDNA deletions and a respiratory chain deficiency with signs of
starvation that lead to the dissipation of ∆ψm (Tyynismaa et al. 2005, personal
comunication). Depolarized mitochondria are unable to fuse with the mitochondrial
network and give arise to separated mitochondrial entities overloaded with
mitochondrial proteins and altered cristae structure. This population of damaged
mitochondria are sequestered and degraded via mitophagy. Damaged mitochondria
that escape from the degradation process, increase in size and thus cannot be
autophagocytosed. Subsequently, in function of time, the enlarge mitochondria
accumulate in subsarcolemmal region of affected muscle fibers (figure 6.1; reviewed
by Mijaljica et al. 2007). Suggestive structures that could represent all the described
autophagy stages have been observed in sections of the Deletor skeletal muscle
using the electron microscopic analysis (Tyynismaa et al. 2005)
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Figure 6.1: Different fates of mitochondria. The elimination mechanisms of
damaged mitochondria from mammalian cells under the starvation condition
(Mijaljica et al. 2007).
Regarding to the previous findings, the autophagy marker LC3 was examined in the
skeletal muscle and the significant increase in amount of LC3-II was detected in the
Deletor  compared  to  the  wild  type  counterparts.  Since  the  amount  of  LC3-II  is
closely  correlated  with  the  number  of  autophagosomes,  this  result  underlies  the
upregulation of mitophagy in the Deletor skeletal muscle and supports the
suggestion of Goffart et al. They have assumed that replication stalling may induce
the increased rate of mitochondrial turnover via mitophagy combined with an
increased rate of replication in order to maintain normal mtDNA steady-state levels
(Goffart et al. 2009). Thus far, the increased level of Opa1 isoforms detected also in
the Deletor skeletal muscle might be consistent with this idea.
Finally, induced autophagy is linked to devastating neurodegenerative diseases and
different  forms  of  cancer,  thus  the  LC3  immunoblotting  analysis  of  the  Deletor
brain, heart and liver tissue samples was performed. Neverthless, significant increase
in  the  amount  of  LC3-II  was  not  observed  in  the  Deletor  tissues  compared  to  the
nontransgenic samples.
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6.6 Tissue-specific pattern of protein acetylation in the
Deletor tissues
The unanswered question remains what is the initiation signal that triggers the
mitochondrial autophagy? Are mitochondria that need to be recycled, marked for
autophagy? It has been observed that fission of mitochondrial network can produce
uneven daughter mitochondria where one daughter mitochondrion with reduced ∆ψm
is unable to re-fuse with the mitochondrial network and is likely to be
autophagocytosed whereas the other daughter mitochondrion with hyperpolarized
∆ψm would fuse again with the network (Twig et al. 2008).
The possible signal might be a posttranslational modification of long-lived proteins,
such as acetylation on lysine residues, since acetylation of ≈ 20% of all
mitochondrial proteins and three mitochondrial protein deacetylases have been
already described (Haigis and Guarente 2006; Kim et al. 2006). The hyperacetylated
proteins would be separated into the depolarized daughter mitochondrion and non-
acetylated to hyperpolarized one. A similar phenomenon has been observed in
budding yeast Saccharomyces cerevisiae and other unicellular systems (Aguilaniu et
al. 2003; Nystrom 2007). A general pattern of mitochondrial protein acetylation in
the skeletal muscle, brain and liver tissue samples was performed, but revealed no
differences between the Deletor and control mice. However, a clear difference in the
general acetylation pattern was found between different tissues. To detect the subtle
changes in the protein acetylation, the pure mitochondria from brain tissue were
isolated using sucrose gradient. No difference in the general pattern was observed
either. However, slight changes in particular bands were detected. Their
identification was not the aim of this study, but their further clarification would be of
great interest to establish. These results showed that marked changes in the overall
number of acetylated proteins do not exist in the Deletor tissues.
Overall, results in this study have proved the Deletor mice as transgenic disease
model that faitfully replicates the features of PEO patients in tissues accumulating
mtDNA deletions without possible differences between gender of transgenic mice,
and that Twinkle-PEO is truly a disease of post-mitotic cells. The results from Opa1
and LC3 analysis in the skeletal muscle may suggest to the fundamental role of
mitophagy as protection against defective mitochondria in late-onset myopathy of
Twinkle-PEO.
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7. Conclusions
The results of this thesis respond to the specific aims:
· The position of the wild type Twinkle contruct in the A mouse line is in the
intron 3 of the TMPRSS11d gene (Transmembrane protease, serine 11D;
OTTMUSG00000028240) on chromosome 5; the dup353-365 Twinkle
contruct in the C mouse line is integrated into the non-coding band A1 on
chromosome 16. The expression and function study of transmembrane serine
protease 11D in the wild type Twinkle overexpressor (A line) is required.
This assay excluded the possible gender differences.
· The presence of mtDNA deletions only in the skeletal muscle and brain
tissues, but not in other tested samples, proved the Twinkle transgenic mice
referred to as Deletor as valuable disease mouse model. Histochemical
analysis of the Deletor intestine supported the Twinkle-PEO as a disease of
post-mitotic tissues.
· Slightly elevated levels of Opa1 isoforms in the Deletor skeletal muscle
might suggest a defect in mitochondrial morphology resulting in
upregulation of mitophagy. In the Deletor brain tissue, a mild increase in the
level of S-OPA1 isoforms was observed, but no clear shift  in the pattern of
Opa1 isoforms was detected either in the brain or in the liver and heart.
· The amount of LC3-II, consistent with enhanced level of mitophagy, was
significantly increased in the Deletor skeletal muscle. No changes in the level
of either LC3-I or LC3-II in other tissues were detected. These results might
indicate an essential role of mitophagy in late-onset mitochondrial myopathy.
· The tissue specific pattern of lysine-acetylated mitochondrial proteins was
observed among different tissues (the heart, brain and skeletal muscle).
Nevertheless, specific pattern of lysine-acetylated proteins, as a signal of
damaged mitochondria in the Deletor tissues, was not detected.
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